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Summary 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas 
(CRISPR-associated) is an adaptive immune system in prokaryotes that uses small 
CRISPR RNA (crRNA) to detect and degrade foreign DNA or RNA. CRISPR-Cas 
systems consist of a CRISPR array and a set of cas genes. Individual crRNAs are 
generated from CRISPR array transcripts and are incorporated into CRISPR 
ribonucleoprotein (crRNP) surveillance complexes that include different Cas 
proteins. The Type I CRISPR-Cas systems are identified by the presence of the 
signature protein Cas3 and utilize a crRNP surveillance complex termed Cascade. 
The Cas protein content of Cascade differs between the CRISPR-Cas subtypes. A 
minimal variant of the Type I-F subtype was identified in Shewanella putrefaciens 
CN-32. The genome of S. putrefaciens CN-32 contains only five Cas proteins (Cas1, 
Cas3, Cas6f, Cas1821 and Cas1822) and a single CRISPR array with 81 spacers. 
This system contains Cas1, an integrase that mediates spacer acquisition, Cas3, the 
target DNA nuclease and Cas6f, the endonuclease that generates mature crRNAs. 
Two additional proteins, Cas1821 and Cas1822, show no apparent sequence 
similarity to any known Cas protein families. A large subunit protein responsible for 
target recognition in other subtypes is absent. RNA-Seq analyses showed that the 
CRISPR array is transcribed and that mature crRNAs are generated. In vivo 
interference activity was demonstrated for this minimal system using a plasmid 
conjugation assay. The interference activity was dependent on the recognition of a 
dinucleotide GG sequence, termed Protospacer Adjacent Motif (PAM). The deletion 
of cas1821 and cas1822 in S. putrefaciens CN-32 abolished the in vivo interference 
activity and resulted in the loss of a stable crRNA pool. A minimal Cascade complex 
was isolated which contained multiple Cas1821 copies, Cas1822, Cas6f and mature 
crRNAs. Recombinant Cas1821 formed helical filaments upon RNA binding and the 
analysis of mutant strains demonstrated that DNA interference depended on 
conserved arginine residues of Cas1822. Cas1822 and Cas3, which contains a 
conserved Cas2-like N-terminus, are discussed to compensate for the absence of 
the large and small subunits present in other Cascade assemblies. These results 
provide insights into the evolution of reduced CRISPR-Cas systems and 
demonstrate Cascade functionality without a large subunit.  
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Zusammenfassung 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas 
(CRISPR-assoziiert) ist ein adaptives Immunsystem in Prokaryoten, das fremde 
DNA oder RNA mit Hilfe von kleinen CRISPR-RNAs (crRNAs) erkennt und diese 
anschließend degradiert. Das CRISPR-Cas System besteht dabei aus einem 
CRISPR-Lokus und einer Gruppe von cas Genen. Individuelle crRNA Moleküle 
werden aus einem langen Transkript des CRISPR-Lokus generiert und im Anschluss 
in CRISPR-Ribonukleoproteinkomplexen inkorporiert. Diese bestehen aus 
verschiedenen Cas-Proteinuntereinheiten bestehen und übernehmen die Funktion 
der zellulären Kontrolle der Immunantwort. Die Typ I CRISPR-Cas Systeme sind 
gekennzeichnet durch die Anwesenheit des Signatur-Proteins Cas3 und des 
CRISPR- Ribonukleoproteinkomplexes mit der Bezeichnung Cascade. Dabei 
variieren die Cas-Proteine in den jeweiligen Cascade-Komplexen der 
unterschiedlichen Subtypen von Typ I CRISPR-Cas Systemen. Eine minimale 
Variante eines Typ I-F Systems konnte in Shewanella putrefaciens CN-32 
identifiziert werden. Das Genom von S. putrefaciens CN-32 enthält dabei nur fünf 
Cas Proteine (Cas1, Cas3, Cas6f, Cas1821 und Cas1822) und einen einzelnen 
CRISPR-Lokus mit 81 Spacer-Sequenzen. Dieses System beinhaltet Cas1, eine 
Integrase welche die Integration neuer Spacer vermittelt, Cas3, eine Nuklease 
welche die Ziel-DNA degradiert und Cas6f, eine Endonuklease die reife crRNAs 
generiert. Die zwei weiteren Proteine, Cas1821 und Cas1822, zeigen keine 
Sequenzähnlichkeit zu allen bisher bekannten Cas-Protein Familien. Die große 
Untereinheit des Cascade-Komplexes, die in anderen Subtypen verantwortlich für 
die Identifizierung der Ziel-DNA ist, fehlt. RNA-Seq Analysen wiesen die 
Transkription des CRISPR-Lokus und die Herstellung der reifen crRNAs nach. 
Interferenz-Aktivität für dieses minimale System konnte in vivo mit Hilfe eines 
Plasmid Konjugations-Assays gezeigt werden. Die Interferenz-Aktivität war dabei 
abhängig von der Erkennung des Dinukleotids „GG“ in unmittelbarer Nähe zur Ziel-
Sequenz. Dieses Motiv wird PAM (Protospacer Adjacent Motif) genannt. Die 
Deletion von cas1821 und cas1822 in S. putrefaciens CN-32 führte zur Aufhebung 
der in vivo Interferenz Aktivität und resultierte gleichzeitig in dem Verlust einer 
stabilen crRNA-Population in der Zelle. Ein minimaler Cascade Komplex konnte 
isoliert werden, der aus Cas1822, Cas6f, mehreren Kopien von Cas1821 und reifer 
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crRNA besteht. Rekombinant hergestelltes Cas1821 bildete durch Bindung von RNA 
lange helikale Filamente aus und die Analyse von Stämmen mit Cas1822 
Mutationen demonstrierte die Abhängigkeit der DNA Interferenz-Aktivität von 
konservierten Arginin-Resten in Cas1822. Es wird diskutiert, ob Cas1822 oder Cas3, 
welches einen konservierten Cas2-ähnlichen Bereich am N-terminalen Ende enthält, 
die Funktion der kleinen und großen Untereinheiten ersetzen zu können. Diese 
Ergebnisse geben Einblicke in die Evolution von reduzierten CRISPR-Cas Systemen 
und demonstrieren Cascade-Funktionalität ohne die Anwesenheit einer großen und 
kleinen Untereinheit. 
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1  Introduction 
Prokaryotes, i.e. Archaea and Bacteria, are ubiquitous in nature and thrive in 
the harshest of environments (1). However, recent estimates show that, depending 
on the environment, the number of viruses exceeds that of prokaryotes by a factor of 
5 to 25 (2,3). In most environments, viruses and prokaryotes are locked in a battle 
for supremacy, which has led to the evolution of prokaryotic virus resistance 
mechanisms (4,5). Defense strategies targeting various stages of a viral infection 
have evolved in prokaryotes. Some defense mechanisms block the viral attachment 
to the cell surface whereas others prevent the injection of a viral genome into the 
host. Mechanisms that (i) degrade viral genomes (restriction modification systems 
(6), Bacteriophage Exclusion (BREX) (7)) or (ii) lead to programmed cell death 
(toxin-antitoxin systems (8)) after infection have also been identified. Most of these 
defense strategies in prokaryotes are innate in nature. In contrast, CRISPR-Cas is a 
recently identified adaptive immune system, which is discussed in detail below. 
 
1.1  CRISPR-Cas systems 
The only adaptive immune system that has been characterized in prokaryotes 
is called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas 
(CRISPR-associated) (9-11). The hallmark of this system is the CRISPR locus that 
contains a series of direct repeats that are separated by sequences that can be of 
viral origin (12-14). Ishino et al. reported the first identification of the CRISPR locus 
in Escherichia coli in 1987 (15). They described five homologous sequences of 29 nt 
length that were separated by 32 nt long variable sequences. Initially, the biological 
significance of these unusual sequences was not realized. However, since 2007 it is 
known that the CRISPR loci and the Cas proteins provide immunity against foreign 
nucleic acids (16). A brief description about the mechanism, distribution and 
classification of these diverse systems is provided below. 
 
1.2 Organization and mechanism 
CRISPR-Cas systems require two components to mediate an immune 
response. The first component is the CRISPR array, which contains a series of 
repeat sequences interspaced by unique DNA fragments called spacers that are 
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derived from conjugative plasmids or viral genomes (Fig. 1.1) (12-14). The second is 
a set of cas genes that are found in the vicinity of the CRISPR array. These genes 
encode for proteins that perform essential functions during each step of the immune 
response (17,18). 
 
  
Figure 1.1: General organization of a CRISPR-Cas system. The CRISPR locus 
consists of a series of direct repeats (black) that are interspaced by short unique 
DNA fragments called spacers (colored). A set of cas genes is associated with the 
locus and is essential for the immune response (modified from (19)). 
 
The immune response of the CRISPR-Cas system is triggered during a viral 
infection of prokaryotic cells, which can result in high mortality of the cells (Fig. 1.2) 
(3). However, a small fraction of surviving cells can incorporate a fragment of the 
viral genome (i.e. the protospacer) into the CRISPR array (20). This stage of the 
immune response during which a new spacer is incorporated into the CRISPR array 
is called acquisition. Although this mechanism is not fully understood, it has been 
found that the Cas proteins, Cas1 and Cas2 and the recognition of a short signature 
sequence called the Protospacer Adjacent Motif (PAM) in the viral genome are 
essential for this process (21-23). After acquiring a new spacer, the CRISPR array is 
transcribed into a long precursor-CRISPR RNA (pre-crRNA) that gets processed to 
CRISPR RNA (crRNA). This stage of the immune response is called processing and 
is performed by a Cas endoribonucleases or RNase III. The Cas endoribonuclease 
e.g. Cas6, recognizes the repeat sequence in the pre-crRNA transcript and cleaves 
within this sequence to generate short crRNAs that contain a hydroxyl-group at their 
5′ ends and a 2′, 3′ cyclic phosphate group at their 3′ ends (24-29). The generated 
crRNAs contain a spacer sequence that is flanked by partial repeat sequences at 
both ends and become an integral part of a ribonucleoprotein complexes (crRNP) 
composed of multiple Cas proteins. During a subsequent viral attack, the crRNA-
loaded crRNP complex scans the viral genome for the protospacer sequence. 
Recognition of the target occurs via Watson-Crick base pairing between the crRNA 
and the protospacer, which results in the degradation of the viral genome (30-34). 
This stage of the immune response is termed interference. 
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Figure 1.2: Schematic representation of the CRISPR-Cas based immune 
response. The three stages of CRISPR-Cas based immunity are acquisition, 
processing and interference (5). During acquisition, Cas1 and Cas2 recognize a viral 
fragment (protospacer) and integrate it into the extending CRISPR locus. The 
CRISPR locus is then transcribed and processed into crRNAs that are incorporated 
into crRNP complexes. These complexes scan and cleave target nucleic acids 
during a subsequent viral infection. (modified from (33)) 
 
1.3 Classification of CRISPR-Cas systems 
The current classification scheme, which is based on phylogenetic analyses of 
Cas proteins, places the CRISPR-Cas systems of bacteria and archaea into three 
main types and eleven subtypes (Fig. 1.3). The three types of CRISPR-Cas systems 
are defined based on the presence of the conserved signature proteins Cas3 (Type 
I), Cas9 (Type II) and Cas10 (Type III), respectively (17,35). Only Cas1 and Cas2, 
which have been found to be essential for acquisition of new spacers, are conserved 
in all CRISPR-Cas systems (21,22,36,37).  
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The three types of CRISPR-Cas systems differ mainly in their crRNP complex 
composition and assembly and the mechanism involved in target recognition and 
cleavage. Type I crRNP complexes are termed Cascade (CRISPR-associated 
complex for antiviral defense) and are constituted by 4 to 7 Cas proteins (30,38,39). 
Similarly, the Type III crRNP complexes are composed of multiple Cas proteins 
(32,40). However, unlike the Type I systems that target DNA in a PAM-dependent 
manner, the Type III systems are PAM-independent and target both RNA and DNA 
(41-44). In contrast, the Type II crRNP complex contains a single large nuclease, 
termed Cas9, that performs the dual role of PAM-dependent target DNA recognition 
and degradation (45,46). Another unique characteristic of the Type II systems is the 
utilization of RNase III for the generation of mature crRNAs (29). A similar function is 
generally performed by the Cas6 endoribonuclease in Type I and Type III systems. 
 
1.4 Distribution of CRISPR-Cas systems 
CRISPR-Cas systems are a widespread in prokaryotes and are found in 
approximately 40% of all sequenced bacterial genomes and nearly all of the 
archaeal genomes (47). Recent reports have also identified CRISPR-Cas systems in 
genomes of bacteriophages which can help in the evasion of the immune response 
of the host (48). The Type I and Type III systems are found in both, bacterial and 
archaeal lineages. However, the Type I systems are widespread among bacteria and 
the Type III systems are more common in archaeal genomes. The Type I subtypes I-
C, I-E and I-F are usually present in bacteria whereas the Type I subtypes I-A, I-B 
and I-D are more prevalent in archaea. The Type III systems are the only CRISPR-
Cas system that can target RNA and hence usually occur together with subtypes of 
Type I CRISPR-Cas system. Thus, by combining two systems that target different 
nucleic acids, the versatility of the CRISPR-Cas based immune response is 
increased. The Type II systems are not widespread and are exclusive found in 
bacteria. (17,35,49). In the following sections, the different types of CRISPR-Cas 
systems are briefly described. 
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Figure 1.3: Current classification of the CRISPR-Cas systems. CRISPR-Cas 
systems are classified into three main types based on the presence of a signature 
gene and into different subtypes based on phylogenetic analyses of the cas genes. 
The signature genes for each type are highlighted in green boxes. The letters above 
the genes indicate major categories of Cas proteins: large subunits (L), small 
subunits (S), crRNP backbone subunits (R), RNases involved in crRNA processing 
(RE) and transcriptional regulators (T) (modified from (17)). 
 
1.5 Type I CRISPR-Cas systems 
CRISPR-Cas systems are classified as Type I based on the presence of the 
conserved signature protein Cas3 and are further divided into six subtypes (I-A to I-
F) (17,35). All Type I crRNP complexes are termed Cascade and are composed of a 
single crRNA and multiple Cas proteins. In most Type I subtypes, the 
endoribonuclease Cas6 cleaves within the repeat sequences of the pre-crRNA to 
generate crRNAs. Cleavage activity of the enzyme is dependent on the recognition 
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of the sequence and structure of the repeat and results in crRNAs that carry an 8 nt 
repeat tag at their 5′ end (27,50,51). Due to the catalytic activity of the enzyme, all 
crRNAs carry a hydroxyl group at the 5′ end and a 2′-3′ cyclic phosphate at the 3′ 
end (31,52). In a few subtypes, further trimming at the 3′ end of the crRNA is 
observed (25,34,53). The Cascade complex is assembled along this mature crRNA 
and recognizes a DNA target based on the presence of a unique PAM sequence and 
the base paring between the crRNA and its complementary DNA strand (Fig. 1.4) 
(31,38,39,54). Binding of the crRNA to its complementary sequence on the target 
DNA displaces the non-complementary strand and results in the formation of an R-
loop structure. This triggers the recruitment of Cas3, a single stranded DNA 
nuclease and ATP-dependent helicase, by the Cascade complex to degrade the 
dsDNA target (55). The metal-dependent HD nuclease domain of Cas3 cleaves the 
non-target strand while its helicase domain unwinds the dsDNA in 3′ to 5′ direction. 
Subsequently, a second Cas3 subunit is recruited to degrade the target strand. 
Cascade complexes from different Type I subtypes have been studied (19) and 
some of them are briefly described below. 
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Figure 1.4: Representation of the mechanism involved in target DNA 
interference by Cascade. The Cascade complex assembles along the crRNA and 
constantly scans for potential targets. Identification of a DNA target is dependent on 
the recognition of the PAM sequence and results in the formation of an R-loop 
structure due to base pairing between crRNA and the target strand. Formation of a 
stable R-loop triggers the recruitment of Cas3, which cleaves the DNA in the 3′ to 5′ 
direction (modified from (19)). 
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1.5.1 Subtype I-E 
The best studied Type I-E system is found in Escherichia coli and its crRNP 
complex termed Cascade consists of a 61 nt crRNA bound by five Cas proteins. The 
mature 61 nt crRNAs contains a 32 nt long spacer flanked by 8 nt and 21 nt long 
repeat sequences at their 5′ and 3′ ends, respectively. They are generated via 
specific Cas6e cleavage of the repeat sequences of a pre-crRNA transcript (31,56). 
After cleavage, Cas6e remains associated with the 3′ hairpin of the mature crRNA 
and initiates the assembly of Cascade around it. The 405 kDa Cascade complex has 
a sea horse-like architecture and is formed by Cas5, Cas6e, Cas7 and two subtype 
specific proteins Cse1 and Cse2, with an uneven protein stoichiometry of (Cas7)6-
(Cse2)2-(Cse1)1-(Cas5)1-(Cas6e)1 (38,39,51). Six copies of Cas7, which contains a 
groove to bind and protect the crRNA, form the helical backbone of the Cascade. 
Additionally, Cas6e and Cas5 bind and protect the 3′ end and the 5′ end of the 
crRNA, respectively. Cse1, the large subunit protein of the Cascade complex, is 
involved in PAM recognition and recruits Cas3 after target recognition, whereas the 
small subunit protein Cse2 functions in stabilizing the R-loop by binding to the 
displaced strand (55).  
 
1.5.2 Subtype I-F 
Many similarities are observed between the subtype I-F and the subtype I-E 
systems (57). Similar to Cas6e, the endoribonuclease Cas6f (also known as Csy4) 
cleaves pre-crRNA in a repeat specific manner and remains tightly associated with 
the 3′ end of the crRNA product (26,58). The generated crRNAs are 60 nt long with 
characteristic 8 nt 5′ repeat handles and a 20 nt 3′ repeat handle containing a stable 
stem loop structure. The tight association of Cas6f to the 3′ handle of the crRNA 
product is essential for RNA protection and I-F Cascade assembly (59,60). The 
crescent-shaped Type I-F Cascade from Pseudomonas aeruginosa has a mass of 
350 kDa and is composed of four Cas proteins with a stoichiometry of (Csy1)1-
(Cas5)1-(Cas7)6-(Cas6f)1 (61). The Cascade backbone is formed by six copies of a 
Cas7 family protein (known as Csy3) that binds to the crRNA. The 5′ and 3′ termini 
are protected by Cas5 (known as Cys2) and Cas6f, respectively (61). Csy1 is 
proposed to perform the functions of target recognition and DNA binding (35,62). 
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Cas3, which is involved in target DNA degradation, contains a HD nuclease domain 
and an ATP-dependent helicase domain and at the N-terminal end is fused with a 
Cas2-like domain (62). This Cas2-Cas3 fusion protein was shown to be involved in 
target DNA degradation and spacer acquisition (37,62).  
 
1.5.3 Other Type I subtypes (I-A, I-B, I-C and I-D) 
In addition to subtypes I-E and I-F, four other Type I subtypes (I-A, I-B, I-C 
and I-D) are found in prokaryotes. As observed for subtypes I-E and I-F, the Cas6 
endoribonuclease is responsible for crRNA generation in all of these subtypes 
except for subtype I-C (51). This subtype does not encode for a Cas6 enzyme and a 
homolog of Cas5 is responsible for crRNA generation (52,63). In most of these 
subtypes, the mature crRNAs contain an 8 nt repeat tag at the 5′ end and a 3′ repeat 
tag that is gradually trimmed. Similar to subtypes I-E and I-F, these subtypes form a 
multi-Cas protein Cascade complex composed of Cas5, Cas7, Cas6 and the large 
and the small subunit proteins (64). In all of these subtypes, Cas7 is proposed to 
bind to the crRNA as a multimer to form the backbone of the Cascade complex (64). 
 
1.5.4 Structure and assembly of Cascade 
Low-resolution EM structures of Cascade complexes are available for most 
Type I subtypes (64,65). Although the Cas protein composition of Cascade differs 
between the Type I subtypes, the general crescent-shape was found to be 
conserved. Recently, crystal structures of the Type I-E Cascade were obtained, 
which provide insights into its architecture and assembly (38,39,66). The structures 
verified that Type I-E Cascade is composed of Cas5, Cas6, Cas7, the two subtype 
specific proteins Cse1 and Cse2 and a 61 nt long crRNA (31). Cas6 
endoribonuclease remains tightly associated with the 3′ end of the crRNA, and is 
thought to initiate the assembly of Cascade (56). Oligomerization of Cas7 along the 
crRNA and the binding of Cas5 to the crRNA’s 5′ repeat tag complete the assembly 
of the basic Cascade scaffold. The comparison of the crystal structures of Cas5 and 
Cas7 suggests that the crRNA binding mechanism is similar for these proteins. 
Superimposition of the structures reveled similarities in a flexible thumb domain and 
a palm domain of the two proteins (38,39,66). In addition to the palm and thumb 
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domains, a finger domain was identified only in Cas7. The binding of Cas5 to the 5′ 
end of the crRNA results in the formation of a hook-like structure in the repeat tag. 
The thumb domain of Cas5 folds over the last nucleotide in the repeat tag and 
interacts with the finger domain of the adjacent Cas7 subunit, creating a kink at this 
point of the crRNA backbone (38,39,66). A similar mechanism is employed during 
the formation of the Cas7 hexamer along the crRNA. The thumb domain of one Cas7 
subunit interacts with both, the palm and the finger domains of the adjacent Cas7 
subunit, resulting in a kink at every sixth nucleotide of the crRNA. Due to these 
interactions, the position of the thumb domain for all Cas7 subunits is comparable 
except for the Cas7 subunit that interacts with Cas6. This Cas7 subunit, upon 
interaction with Cas6, rotates its thumb domain outwards (38,39,66). The intertwined 
Cas protein arrangement separates the crRNA into six segments, in which one 
nucleotide is splayed and the following five nucleotides are accessible for 
coordination with target DNA (Fig. 1.5). Upon target DNA hybridization, the thumb 
domain of Cas7 also causes a kink in the target DNA backbone, which destabilizes 
the dsDNA and initiates the R-loop formation (38,39,66). The assembly of an active 
Cascade is completed by binding of the small subunit (Cse2) dimer and the large 
subunit (Cse1) to the Cascade backbone at the 3′ and 5′ ends of the crRNA, 
respectively. Both proteins form a basic groove along the belly of Cascade that is 
necessary for the binding of the non-target strand after R-loop formation (38,39,66). 
Additionally, Cse1 undergoes structural changes upon target DNA binding which 
results in the recruitment of the Cas3 nuclease (67). This arrangement of the Type I-
E Cas proteins along the crRNA results in an active Cascade that is constantly 
screening for potential targets. Crystal structures of Cas5 and Cas7 proteins are 
available for other Type I subtypes. The comparison of these structures revealed a 
similar domain organization to E. coli Cas5 and Cas7 from Type I-E (64). These 
observations suggest that the mechanism involved in the basic Cascade backbone 
assembly might be conserved for all Type I subtypes. 
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A    B      
  
Figure 1.5: Structure of the Type I-E Cascade. Depicted are the (A) Cartoon 
structure and the (B) crystal structure of type I-E Cascade (68). The complex 
contains 11 protein subunits with the following stoichiometry (Cse1)1-(Cse2)2-
(Cas5)1-(Cas7)6-(Cas6)1 and a 61 nt long crRNA. Binding of Cas5 and Cas6 to the 
crRNA protects the 5′ end and 3′ end, respectively. The crescent shaped structure of 
Cascade is a result of the kinking of the crRNA by the thumb domains of Cas5 and 
Cas7. The two Cse2 subunits bind at the 3′ end of the crRNA via protein:protein 
interactions with Cas7. The large subunit Cse1 is positioned at the 5′ end of the 
crRNA and interacts with Cas5, Cas7 and Cse2 (38,39,66) (modified from (68)). 
 
1.6 Type II CRISPR-Cas systems 
Type II CRISPR-Cas systems are exclusively found in bacteria and employ 
the stand-alone signature protein Cas9 to perform DNA target recognition and 
degradation (46,69). One of the interesting features of the Type II systems is the 
absence of the endoribonuclease Cas6. Instead, the generation of crRNAs in Type II 
systems involves Cas9, the bacterial host enzyme RNase III and a tracrRNA (trans-
activating crRNA). Biogenesis of crRNA begins with the formation of a RNA duplex 
between the anti-repeat sequence of the tracrRNA and the repeats of the pre-crRNA. 
This duplex, upon stabilization by Cas9, is recognized and cleaved by RNase III (28). 
The obtained crRNAs contain the spacer sequence at the 5′ terminus and the repeat 
sequence at the 3′ terminus and remain associated with the tracrRNA (28,29).  
Although variation in the sequences of Cas9 among Type II containing 
organisms were observed, three conserved features were detected: (i) the HNH and 
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the RuvC nuclease domains, (ii) an arginine rich motif and (iii) a general globular 
architecture (46,70,71). Cas9 utilizes the tracrRNA:crRNA duplex to recognize and 
bind its target in a PAM dependent manner during interference (Fig. 1.6). On target 
binding, the HNH nuclease domain cleaves the DNA strand that is complementary to 
the spacer region of the crRNA, while the RuvC nuclease domain cleaves the non-
target DNA strand (72,73). Target recognition is dependent on base paring between 
the crRNA and the target and the presence of a PAM on the DNA (72,73). Although, 
few mutations in the protospacer sequence are tolerated by this system, mutations in 
the PAM sequence result in the target evading CRISPR-Cas mediated immunity. In 
Streptococcus pyogenes, it was shown that two conserved arginine residues R1333 
and R1335 are essential for the recognition of the PAM sequence ′NGG′ (45). 
Mutations of these residues abolished the targeting ability of the Type II CRISPR-
Cas system. 
 
 
Figure 1.6: Interference mechanism of a Type II CRISPR-Cas system. The 
system contains a stand-alone Cas9 enzyme that performs the functions of DNA 
target binding and degradation. The crRNAs are generated with the help of a 
tracrRNA and the host enzyme RNase III. The crRNA:tracrRNA duplex guides Cas9 
to recognize the DNA target in a PAM-dependent manner. Two separate nuclease 
domains of the protein cleave the DNA target (modified from (74)). 
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1.7 Type III CRISPR-Cas systems 
The Type III CRISPR-Cas systems are characterized by the presence of the 
signature protein Cas10, but share significant similarities with Type I systems 
(17,35). The crRNAs in Type III systems are also generated by the Cas6 
endoribonuclease and form an integral part of a multi-Cas protein crRNP complex 
that is necessary for the recognition and degradation of target nucleic acids. The 
mature crRNAs contain the standard 8 nt 5′ repeat tag. However, trimming of the 
crRNA at the 3′ ends is observed and results in two crRNA variants that differ by 6 nt 
in length (75,76). The Type I and Type III systems are clearly distinguished by their 
mode of recognition and selection of the targets. Type I systems exclusively target 
dsDNA and rely on the PAM sequences to distinguish between self and non-self 
targets. In contrast, Type III systems target both ssRNA and dsDNA (40,76-78). It 
was recently shown that transcription across dsDNA is necessary for cleavage of the 
target DNA by Cas10 of the Type III Csm complex (78). This activity was PAM-
independent and instead relied on the mismatches between the 5′ repeat tag of the 
crRNA and the 3′ region of the target DNA to prevent autoimmunity. Csm3, the 
backbone protein of the Csm complex is responsible for ssRNA cleavage, for which 
a self-targeting prevention mechanism was not detected (44).  
 
1.8 The CRISPR-Cas system of Shewanella putrefaciens CN-32  
Shewanella putrefaciens is a gram-negative bacterium that belongs to the 
class of gammaproteobacteria. The rod shaped organism contains a polar flagellum 
for motility and is usually found in marine environments. S. putrefaciens is not 
considered to be a typical human pathogen. However, cases of benign skin and soft 
tissue infections, peritonitis, biliary tract infection and bacteremia in immune-
compromised patients have been linked to the presence of S. putrefaciens (79). In 
the absence of oxygen, S. putrefaciens has been reported to use a wide variety of 
terminal electron acceptors that include nitrate, nitrite, fumarate, thiosulphate, 
elemental sulphur, trimethylamine N-oxide and, the particulate metal oxides of 
Mn(IV) and Fe(III) (80). Furthermore, the strain S. oneidensis MR-1 is used as a 
model organism for anaerobic respiration and electron transport linked metal 
reduction (81,82). 
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S. putrefaciens is a facultative anaerobe and can be cultured both aerobically 
and anaerobically, with an optimal growth temperature of 30°C. Few species of 
Shewanella have been reported to grow at temperatures ranging from 3°C to 35°C 
(83). Additionally, genetic manipulation tools and gene expression systems for S. 
putrefaciens are available (84).  
The genome of Shewanella putrefaciens CN-32 contains a single CRISPR 
locus. The locus contains 81 spacers and pseudo-palindromic repeats that are 28 nt 
long. Five cas genes were found associated with this CRISPR locus. This system 
was classified as a variant of the Type I-F system and was first described in 
Photobacterium profundum SS9 (PBPRB1995 - PBPRB1991) (Fig. 1.7) (35). The 
system contains genes that encode for Cas1, the integrase that mediates spacer 
acquisition, Cas3, the target DNA nuclease and Cas6f, the endonuclease that 
generates mature crRNAs. Two additional genes showed no detectable sequence 
similarity to known cas gene families and a gene encoding for the large subunit could 
not be detected (35). The large number of spacers in the CRISPR locus and the 
conservation of the gene operon in several proteobacterial species suggest that this 
variant system is active. 
 
 
Figure 1.7: Genome organization of the type I-F variant system identified in 
Photobacterium profundum SS9. The system contains five Cas proteins including 
Cas1, Cas3 and Cas6. The two additional proteins share no obvious homology to 
known Cas protein families (modified from (35)). 
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1.9 Aim of this work 
A variant Type I-F CRISPR-Cas system was identified In Shewanella 
putrefaciens CN-32. The system consists of a CRISPR locus containing 81 spacers 
and five associated cas genes. Three of these genes, Sputcn32_1819, 
Sputcn32_1820 and Sputcn32_1823 encode proteins that belong to Cas1, Cas3 and 
Cas6 protein families, respectively. The two additional genes cas1821 
(Sputcn32_1821) and cas1822 (Sputcn32_1822) encode proteins that share no 
detectable homology with known Cas protein families. Additionally, a large Cascade 
subunit protein is absent in this system. Nevertheless, this minimal cas gene operon 
organization is conserved in several proteobacterial species. One aim of this study 
was to verify that this system is active in vivo. Subsequently, the interference activity 
of this system was investigated with a focus on the functional characterization of the 
two unclassified Cas proteins, Cas1821 and Cas1822. 
 
The Cascade crRNP complexes responsible for DNA target recognition in 
Type I systems are composed of a crRNA and 4 to 7 Cas proteins. The second aim 
of this study was the analysis of a minimal Cascade of S. putrefaciens CN-32 that is 
proposed to contain only three proteins: Cas1821, Cas1822 and Cas6. Finally, the 
elucidation of the minimal Cascade architecture can be used to define general 
assembly and functionality concepts for Type I Cascade complexes. 
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2 Results 
2.1 Identification of a minimal CRISPR-Cas subtype in Shewanella 
putrefaciens CN-32 
A minimal Type I-F variant CRISPR-Cas subtype was first described for 
Photobacterium profundum SS9 (PBPRB1995-PBPRB1991) (35). A similar system 
was found in Shewanella putrefaciens CN-32 (Fig. 2.1) and it harbors a single 
CRISPR array with 81 spacers and only five cas genes: cas1 (Sputcn32_1819), cas3 
(Sputcn32_1820), cas6f (Sputcn32_1823), cas1821 (Sputcn32_1821) and cas1822 
(Sputcn32_1822). The comparison of this system with the subtype I-F system 
present in the Shewanella sp. strain W3-18-1 illustrates the loss of the large subunit 
and the diversification of the Csy1 – Csy3 proteins (Fig. 2.1). These CRISPR-Cas 
systems share 100% amino acid identity for the flanking Cas1 and a CRISPR-array 
adjacent DinG-helicase. In addition, the Cas6f endonuclease and the N-terminal 
portion of the Cas3 nuclease show significant sequence identity. However, the other 
Cas proteins that constitute the subtype I-F Cascade (Cas5 (Csy2), Cas7 (Csy3) and 
the large subunit (Csy1)) diverged drastically from the two Cas proteins Cas1821 
and Cas1822. A large subunit candidate is absent in this minimal variant. Homology 
searches of Cas1821 and Cas1822 revealed the presence of similar I-F variant 
systems in few other beta- and gammaproteobacteria. These include the human 
pathogens Legionella pneumophila (strain 2300/99 Alcoy) and Vibrio cholerae (strain 
TM 11079-80). 
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Figure 2.1: Comparison of CRISPR-Cas systems in S. putrefaciens strains. 
Schematic diagrams show the single CRISPR-Cas systems from Shewanella sp. 
W3-18-1 (Sputw3181_2191 - Sputw3181_2185, Type I-F) and S. putrefaciens CN-32 
(Sputcn32_1819 - Sputcn32_1824, Type I-F variant). Cas1, DinG and the N-terminal 
94 amino acids of the Cas3 proteins share 100% aa identity. The C-terminal Cas3 
portion and the putative Cascade components Cas1821 and Cas1822 do not reveal 
significant protein similarity. 
 
2.2 In silico characterization of the minimal Type I-F variant 
system 
2.2.1 Characterization of Sputcn32_1823 
The S. putrefaciens CN-32 CRISPR array contains partially palindromic 
repeats of 28 nt length that are separated by ~32 nt long spacers (only 3 of the 81 
spacers are 33 nt in length). The minimum free energy structure of the repeat as 
predicted by RNAplot (85) revealed a five base-pair stem-loop formed by the 
palindromic region (Fig. 2.2A). A similar pseudo palindromic repeat was observed for 
the Type I-F system found in Pseudomonas aeruginosa (26). It was shown that 
Cas6f generates crRNAs by recognizing the stem-loop of the repeat and cleaving at 
the base of the stem loop at the 3′ end (26). BLAST analyses identified 
Sputcn32_1823 as a member of the Cas6 protein family with 37% sequence identity 
to Cas6f from P. aeruginosa (Fig. 2.2B). Additionally sequence alignment of the two 
proteins identified a conserved histidine residue at position 29, which was reported to 
be essential for the endoribonucleolytic activity of Cas6f from P.aeruginosa (Fig. 
2.2B) (26). Therefore, Sputcn32_1823 (Cas6f) was predicted to be the enzyme 
responsible for the biogenesis of crRNA in S. putrefaciens CN-32. 
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Figure 2.2: Sputcn32_1823 is a Cas6f homolog. (A) Predicted minimum free 
energy structure of the repeat sequence of the S. putrefaciens CN-32 CRISPR array. 
(B) Sequence alignment of Cas6f from S. putrefaciens and P. aeruginosa. The 
identical residues are colored in blue and the catalytic histidine residue is marked by 
an asterisk. 
 
2.2.2 Characterization of Sputcn32_1820 
A Type I-F system, similar to the system present in Shewanella sp. W3-18-1 
was identified in Pectobacterium atrosepticum. The Cas3 protein of this system was 
reported to contain an HD nuclease domain, a helicase domain and a Cas2 like 
domain at the N-terminus of the protein (62). Although the overall sequence similarity 
between Sputcn32_1820 and this protein was very low, high identity was observed 
at the N-terminal region. The tertiary structure prediction of Cas3 protein from S. 
putrefaciens CN-32 using Phyre2 and I-Tasser identified a Cas2-like fold for this 
region (86,87) (Fig. 2.3A). Additionally, the domain prediction tool Prosite identified a 
HD nuclease domain and a helicase domain (belonging to the Superfamily 2 
helicases) at the C-terminal end of the protein (88). Hence, as observed in Type I-F 
systems, Sputcn32_1820 (Cas3) is a fusion protein that contains both Cas2 and 
Cas3 domains (Fig. 2.3B). The HD nuclease domain of Cas3 from Streptococcus 
thermophilus was shown to cleave ssDNA in the presence of transition metals ions 
like Mg2+ or Mn2+ whereas the helicase domain unwound dsDNA in the 3′ to 5′ 
direction by utilizing ATP (89). Therefore, S. putrefaciens CN-32 Cas3 is predicted to 
have a similar function and is proposed to degrade foreign DNA during interference. 
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Sputcn32_1820       SSO1404 (Cas2) 
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Figure 2.3: Organization of Cas3 from S. putrefaciens CN-32. (A) 3D predicted 
structure of the N-terminal 100 aa of Cas3. The predicted structure was similar to 
Cas2 from Sulfolobus solfataricus (SSO1404, in blue) with which an 11% aa identity 
was shared. (B) Schematic representation of the predicted domains of Cas3. 
 
2.2.3 Characterization of Sputcn32_1821 and Sputcn32_1822 
The variant Type I-F system harbors two hypothetical genes in the cas 
operon. The two proteins Cas1821 and Cas1822 appear to replace the Type I-F 
Cascade forming Cas proteins Csy1 (large subunit), Csy5 (Cas5) and Csy3 (Cas7). 
Makarova et al. classified these two proteins as Cas7-like and Cas5-like based on 
their length and the position of the respective genes in the operon (35). However, 
psi-BLAST analyses could not identify similarities between these proteins and the 
Cas7 and Cas5 protein families. Accordingly, phylogenetic analyses with Cas7 and 
Cas5 protein families grouped these proteins and its homologs into a separate 
cluster. Interestingly, Cas1821 shared an evolutionary relationship with the proteins 
from the Type I-F system, whereas Cas1822 was related to the proteins from the 
Type I-C system (Appendix 1 and 2). Further bioinformatic analyses using the 
domain prediction tool, Prosite and the tertiary structure prediction tools, Phyre2 and 
I-Tasser, could not identify conserved domains and folds in both Cas1821 and 
Cas1822. Therefore, the biochemical functions of these unique Cas proteins could 
not be predicted using bioinformatic tools and analyses.  
The variant Type I-F system is characterized by the absence of the large 
subunit protein. This variant system was identified in nine mesophilic beta- and 
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gamma-proteobacteria: S. putrefaciens (strains CN-32 & 200), Oligella ureolytica 
(strain DSM 18253), Pseudoalteromonas tunicata (strain D2), L. pneumophila (strain 
2300/99 Alcoy), Oxalobacter formigenes (strain OXCC13), P. profundum (strain 
SS9), V. cholerae (strain TM 11079-80) and Methylophaga nitratireducenticrescens. 
Phylogenetic profiling of these genomes was performed using the Phylogenetic 
profiler tool offered by the JGI platform, to identify proteins that could substitute for 
the large subunit (90). S. oneidensis MR-1 genome, which lacks a CRISPR-Cas 
system, was included in the analyses as an outgroup. Therefore, genes in S. 
putrefaciens CN-32 that had homologs in S. oneidensis MR-1 were not considered 
during the analyses. Out of the 596 genes that were not shared between the two 
genomes, the 5 cas genes and 16S and 23S ribosomal RNA modification enzymes 
were identified to be conserved with > 95% identity (Table 2.1) in the nine Type I-F 
variant system containing genomes. On repeating the analyses with Shewanella sp. 
W3-18-1 genome, which encodes the subtype I-F CRISPR-Cas system, as an 
outgroup, only cas1821, cas1822 and cas6 were conserved in all Type I-F variant 
containing organisms. However, a potential candidate responsible for the PAM 
recognition function could not be identified. Additionally, in S. putrefaciens CN-32, 
downstream of the CRISPR array an ATP-dependent DNA helicase DinG 
(Sputcn32_1824) was observed. Makarova et al. predicted this protein to be a 
functional component of the Type I-U system (35). Therefore, DinG could be a 
potential enzyme that took over the role of the large subunit in the variant Type I-F 
system. 
 
Table 2.1: List of conserved proteins obtained from phylogenetic profiling of 
the nine genomes. 
 
Locus Tag 
 
Annotation 
Percentage 
identity 
Sputcn32_0834 23S rRNA pseudouridine746 synthase RluA 99.6% 
Sputcn32_0922 RNA pseudouridylate synthase family protein 97.1% 
Sputcn32_0952 Transcriptional regulator LysR family 100% 
Sputcn32_1000 16S rRNA pseudouridine synthase RluA family 99.7% 
Sputcn32_1019 16S rRNA pseudouridine synthase RsuA family 99.6% 
Sputcn32_1022 23S rRNA pseudouridine1911/1915/1917 synthase RluD 100.0% 
Sputcn32_1339 tRNA pseudouridine65 synthase TruC 98.9% 
Sputcn32_1574 23S rRNA pseudouridine955/2504/2580 synthase RluC 99.7% 
Sputcn32_1819 Cas1 98.8% 
Sputcn32_1820 Cas3-HD 99.6% 
Sputcn32_1821 Conserved hypothetical protein 100.0% 
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Sputcn32_1822 Conserved hypothetical protein 100.0% 
Sputcn32_1823 Csy4 100.0% 
Sputcn32_2013 Alanine dehydrogenase Ald 100.0% 
Sputcn32_2231 23S rRNA pseudouridine2457 synthase RluE 97.4% 
Sputcn32_2398 23S rRNA pseudouridine2605 synthase RluB 100.0% 
Sputcn32_2441 tRNA pseudouridine38-40 synthase TruA 100.0% 
Sputcn32_2488 23S rRNA pseudouridine synthase RluA family 100.0% 
Sputcn32_2832 tRNA pseudouridine55 synthase TruB 99.7% 
Sputcn32_2938 16S rRNA pseudouridine synthase RluA family 98.7% 
 
2.3 Characterization of the crRNAs of the Type I-F variant 
CRISPR-Cas system 
2.3.1 The CRISPR array in S. putrefaciens CN-32 is transcribed and processed 
in vivo 
Activity of the variant Type I-F system has not been observed. One of the 
hallmarks of an active CRISPR-Cas system is the presence of crRNAs. To identify 
crRNAs small RNA molecules were isolated from S. putrefaciens CN-32 and 
subjected to RNA-Seq analyses. Sequencing of crRNAs required T4 PNK treatment 
of the isolated small RNA molecules during Illumina Hiseq2000 library preparation, 
which indicates the presence of crRNA 5′ hydroxyl termini. More than 11 million 
sequence reads were mapped to the S. putrefaciens CN-32 reference genome. The 
presence of all 81 crRNA transcripts could be verified and precursor transcript 
processing generated the expected 8 nt repeat tags at the crRNAs’ 5′-ends (5′-
CUUAGAAA-3′) and a 20 nt repeat tag at the 3′-termini (Fig. 2.4 Insert). 73,377 
reads mapped to the CRISPR locus, indicating a lower crRNA abundance in 
comparison to very similar RNA-Seq studies for type I-A and type I-B systems 
(25,34). A minimum free-energy five base pair stem-loop was predicted in the 3′-
repeat tags of all crRNAs, which could explain the absence of additional 3′-terminal 
degradation for most crRNAs (Fig. 2.4). The abundance of the individual crRNAs 
varied significantly. 
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Figure 2.4: Analysis of CRISPR RNA abundance and termini. The coverage plot 
of S. putrefaciens CN-32 sequence reads (Illumina HiSeq2000) indicates the 
variable abundance of the individual crRNAs. Mature crRNAs contained 5′-terminal 8 
nt tags (5′-CUUACAAA-3′) and 20 nt 3′-ends without further trimming events (inset). 
Spacers that are marked with an asterisk were tested for interference activity (see 
Fig. 2.7 and Fig. 2.9). 
 
2.3.2 Cas6f is responsible for crRNA biogenesis 
Bioinformatic analyses identified Sputcn32_1823 as a homolog of Cas6f in 
this variant Type I-F system. To verify its responsibility for crRNA processing, the 
recombinant protein was produced in E. coli with a C-terminal 6x His-tag. Inclusion 
body formation was observed when the protein was produced at 37°C. However, 
protein production at 18°C resulted in soluble protein, which was purified to >95% 
purity as evaluated via SDS-PAGE after Ni-NTA chromatography. The purified Cas6f 
was highly unstable and precipitated within 12h. Nevertheless, it showed 
endonuclease activity and cleaved a 100 nt long spacer3-repeat–spacer4 transcript 
(Fig. 2.5). Comparison of the obtained fragment sizes with the RNA-Seq analyses 
revealed the point of cleavage to be at the base of the stem-loop (Fig. 2.5A). 
S. putrefaciens CN-32 Cas6f has a 37% amino acid identity with Csy4 (Cas6f) 
from P. aeruginosa. A sequence alignment of the two proteins verified a conserved 
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histidine residue at position 29 that was previously reported to be essential for Cas6f 
activity (Fig. 2.2B) (26). Mutation of this His29 residue to Ala abolished the 
endonuclease activity (Fig. 2.5B). 
 
A 
 
B 
 
Figure 2.5: Cas6f endonuclease activity. (A) Schematic representation of the RNA 
transcript used in the Cas6f nuclease assay. The site of cleavage was determined 
based on the fragment sizes obtained from the nuclease assay and RNA-Seq 
analyses. (B) Recombinant Cas6f endonuclease cleaved spacer3-repeat-spacer4 
RNA transcripts into two fragments of ~60 nt and ~40 nt length (left panel, toluidine 
blue stained urea-polyacrylamide gel). Mutation of the catalytic His29 abolished the 
endonuclease activity of the protein (right panel) for RNA transcripts labeled at 5′ 
end with γ-[32P]-ATP. 
 
2.4 The Type I-F variant CRISPR-Cas system show in vivo 
interference activity 
2.4.1 Identification of the PAM sequence 
Spacer sequences are known to match viral genomes and conjugative 
plasmids. Therefore, the tool CRISPRTarget was used to search for potential targets 
of the spacers from S. putrefaciens CN-32 (91). Of the 81 spacers, only spacer 33 
(~97% identity between spacer and target) and spacer 34 (100% identity between 
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spacer and target) were found to potentially target Shewanella sp. W3-18-1 and 
Shewanella sp. MR7, respectively (Fig. 2.6). In both cases, the di-nucleotide GG was 
found at the 3′ end of target strand match. Hence, GG was considered to be the 
potential PAM sequence, which is in agreement with computational predictions by 
Mojica et al. (23). 
 
 
Figure 2.6: Identification of the potential PAM. Potential targets for crRNA34 and 
crRNA33 (repeat sequence are indicated in grey and spacer sequence in black) 
were identified by the CRISPRtarget tool in prophages found in Shewanella sp. W3-
18-1 and Shewanella sp. MR7, respectively. In both cases, the di-nucleotide ′GG′ 
PAM sequence (in red) was identified at the 3′ end of the target strand.   
 
2.4.2 In vivo interference activity 
Due to the low crRNA abundance, detection of CRISPR-Cas-mediated DNA 
interference activity in S. putrefaciens CN-32 required the establishment of a 
sensitive conjugation-based in vivo assay (Figure 2.7A). Two conjugative plasmids 
were used: (i) a non-target control plasmid (pNT = pBBR1MCS2) and (ii) a target 
plasmid (pT) containing the 13th spacer of the S. putrefaciens CN-32 CRISPR array 
(spacer13) and the PAM sequence ′GG′ at the 3′ end of the sequence 
complementary to spacer13 on the target strand. The two plasmids pNT and pT 
were conjugated from E. coli WM3064 into S. putrefaciens CN-32. In addition, 
markerless gene deletions were constructed for the genes cas1, cas3, cas1821 and 
cas1822 and the two plasmids were conjugated into these deletion strains. The 
colonies carrying pNT or pT were counted and the conjugation efficiency was 
calculated as pT over pNT. Relative conjugation efficiency (pT/pNT) below 1 
indicates interference activity. Interference was observed in wild-type S. putrefaciens 
CN-32 cells (Fig. 2.7B) and the Δcas1 strain, which is in agreement with an exclusive 
role of Cas1 in spacer acquisition. In contrast, DNA interference activity was not 
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apparent in the Δcas1821 and Δcas1822 strains and significantly reduced in the 
Δcas3 strain. To investigate the reason for this loss of interference activity, the 
crRNA pool in these deletion strains was assayed. Total RNA was isolated from the 
different S. putrefaciens CN-32 cells and Northern blot analyses were performed 
using a radioactively labeled probe against the crRNA repeat sequence (Fig. 2.7C). 
The production of crRNAs was observed in wild-type cells and the Δcas1 and Δcas3 
deletion strains. However, crRNAs were absent in the Δcas1821 and Δcas1822 
strains. These results suggest that Cas6f generates mature crRNAs, which are then 
bound by Cas1821 and Cas1822 to maintain a stable crRNA pool in the cell. Thus, 
the absence of interference activity for the Δcas1821 and Δcas1822 strains 
correlates with the absence of crRNAs in these cells.  
 
 
Figure 2.7: Conjugation assays reveal DNA interference activity of the S. 
putrefaciens CN-32 CRISPR-Cas system. (A) The experimental set-up of the 
conjugation assay is depicted. Two plasmids were used: (I) a control plasmid (pNT, 
plasmid non-target) and (II) a plasmid containing a PAM sequence (light grey) and a 
sequence matching spacer 13 (dark grey) of the S. putrefaciens CN-32 CRISPR 
array (pT, plasmid target). The number of S. putrefaciens CN-32 colonies carrying 
each plasmid was counted and the conjugation efficiency was determined. 
Interference is observed if pT/pNT is lower than 1 in triplicate assays. (B) The 
pT/pNT ratio is calculated for conjugation assays into S. putrefaciens CN-32 wild-
type cells and strains containing deletions of genes encoding Cas1, Cas3, Cas1821, 
Cas1822 and H-NS. (C) Northern blot analyses were performed with extracted total 
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RNA from S. putrefaciens CN-32 wild-type and cas gene knockout strains using a 5′-
γ-[32P]-ATP labeled probe complementary to the repeat sequence. A stable crRNA 
pool was absent in the S. putrefaciens CN-32 Δcas1821 and Δcas1822 strains. 
 
2.4.3 H-NS regulates the variant Type I-F CRISPR-Cas system 
Previous studies of the type I-E CRISPR-Cas system in E. coli revealed that 
the heat-stable nucleoid-structuring (H-NS) protein, a global transcriptional 
repressor, can regulate the expression of CRISPR-Cas systems (92). A homolog of 
this protein was identified in S. putrefaciens CN-32. To assay its effect on the 
interference activity, a ΔH-NS S. putrefaciens CN-32 strain was constructed. A slight 
increase in the interference activity was observed for this strain in the conjugation-
based assay (Fig. 2.7B). Although an increase in crRNA abundance could not be 
observed via northern blot analysis, a two-fold increase in cas gene transcripts was 
detected via qRT-PCR (Fig. 2.8), which could explain the observed increase in the 
interference activity. 
 
 
Figure 2.8: Analysis of cas gene transcript abundance. qRT-PCR analysis was 
performed to compare the cas gene transcript abundance between S. putrefaciens 
wild-type and ΔH-NS strains. 
 
2.4.4 The CRISPR-Cas system recognizes PAM sequences and targets dsDNA 
Conjugation between the donor and the recipient cell requires the transfer of 
one strand of plasmid DNA through an intercellular cytoplasmic bridge, beginning at 
the origin of transfer and progressing in 5′ to 3′ direction. The transferred strand is 
converted into circular double-stranded plasmid DNA in the recipient and a new 
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strand is synthesized in the donor to replace the transferred strand. In our 
experimental setup, the transferred strand can be directly targeted by the crRNA as it 
contains the sequence complementary to spacer13. To address if the minimal I-F 
variant system targets ssDNA or dsDNA, a plasmid was constructed with the 
sequence of spacer13 on the transferred strand. Thus, the complementary target of 
crRNA 13 exists only after synthesis of the second strand in the recipient cell. The 
relative conjugation efficiency (pT/pNT) for this plasmid in both, wild-type and ΔH-NS 
strains was comparable to the previous construct (Fig. 2.9A). This confirms that the 
I-F variant CRISPR-Cas system targets dsDNA. 
To investigate if the absence of a large subunit had an effect on the 
recognition of PAM sequences, variants of the targeted plasmid were constructed 
that contained mutations in the PAM sequence. These variants contained the 
dinucleotides AG, GA, AA or CC at the 3′ end of the spacer13 match on the target 
strand. In addition, a plasmid was constructed with the first 10 nt of the target being 
replaced by a poly-A stretch. The relative conjugation efficiency (pT/pNT) of these 
constructs highlighted a loss of interference activity and demonstrated that PAM 
sequences are recognized in S. putrefaciens CN-32 (Fig. 2.9A). 
The RNA-Seq analysis of crRNA production revealed a highly variable crRNA 
abundance profile (Fig. 2.4). Therefore, the effect of the abundance of individual 
crRNAs on interference activity was investigated. Thus, targeted plasmids with GG 
PAM sequences in which the spacer13 target was replaced with spacer1, spacer3 
(abundant crRNAs) or spacer15, spacer20 and spacer34 targets (low crRNA 
abundance) were generated. The conjugation assays verified that highly abundant 
crRNAs (spacers1, 3, 13) yield efficient interference activity (Fig. 2.9B). In 
agreement, the observed absence of stable crRNAs with spacer34 in S. putrefaciens 
CN-32 correlated with a complete loss of interference activity. However, interference 
activity was observed for crRNAs with spacer15 and spacer20 even though only 
minimal amounts of these crRNAs were detected in our RNA-Seq studies (Fig. 
2.9B). These results indicate that variable crRNA abundance is a factor that can 
influence the efficiency of DNA targeting. 
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Figure 2.9: Analysis of the DNA target specificity of the S. putrefaciens CN-32 
CRISPR-Cas system. Conjugation assays (see Fig. 2.7) were used to analyze 
plasmid DNA target variants for DNA interference in S. putrefaciens CN-32 cells. (A) 
Interference was observed if the transferred DNA strand contained a sequence 
complementary to the crRNA13 (sp13-GG) or a sequence identical with spacer13 
(sp13-GG*). Interference was evident for the wild-type and ΔH-NS strains, which 
contained all cas genes. However, the deletion of cas3 (Sputcn32_1820) or cas1822 
abolished interference activity. The presence of the PAM sequence GG at the 3′ end 
of the DNA target was essential for the interference activity and PAM mutants (sp13-
AG, sp13-GA, sp13-AA or sp13-CC) and a 10 nt poly-A sequence disrupting 
crRNA/DNA complementarity (sp13-polyA) were not targeted. (B) DNA interference 
activity was dependent on spacer sequence or crRNA abundance (Spacers 1, 3, 13, 
15, 20 and 34, see Fig. 2.4). 
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2.5 In vitro characterization of Cas proteins 
2.5.1 Characterization of recombinant Cas3 as an ssDNA nuclease 
Bioinformatic predictions indicated Cas3 to be a fusion protein with an N-
terminal Cas2 like domain fused to the nuclease and the helicase domains of Cas3. 
In other Type I systems, Cas3 was reported to contain metal-dependent ssDNA 
nuclease activity responsible for target DNA degradation. The reduction in the 
interference activity for the Δcas3 S. putrefaciens strain suggests a similar role for 
the S. putrefaciens Cas3 protein. Thus, the recombinant protein was produced in E. 
coli to test its activity in vitro.  
Soluble recombinant Cas3 was produced as a SUMO-tag fusion construct in 
cells grown in NZ-Amine media and purified via Ni-NTA affinity chromatography (Fig. 
2.10A). Protein purity was relatively low and could not be improved by including 
additional purification strategies like ion exchange chromatography and size-
exclusion chromatography. Additionally, the removal of the SUMO-tag from Cas3 
using SUMO-protease was unsuccessful. Hence, to improve the yield and purity of 
the protein several different expression conditions were tested (Table 2.2). However, 
in all of the tested conditions, the protein was not produced or formed inclusion 
bodies. Therefore, the obtained SUMO-Cas3 was assayed for its ssDNA nuclease 
activity. When incubated in the presence of the transition metal ions Mg2+ or Mn2+, 
Cas3 cleaved 5′-[γ-P32]–ATP labeled ssDNA. The absence of these metal ions or the 
addition of EDTA abolished the nuclease activity (Fig. 2.10B). For S. thermophilus 
Cas3, the His76 and Asp77 residues in the HD nuclease domain were shown to be 
essential for ssDNA hydrolysis (89). These residues were also identified in the HD 
domain of S. putrefaciens CN-32 Cas3. The His156 and Asp157 residues were 
mutated to alanine residues. However the variant proteins could not be produced in 
E. coli. 
 
Table 2.2: List of expression conditions tested for the production of soluble 
recombinant Cas3. 
Construct Medium Temperature Induction of protein 
production 
Cas3 with N-terminal maltose 
binding protein (MBP)-tag 
LB 37°C 1 mM IPTG, 3h at 37°C 
Cas3 with N-terminal MBP-tag NZA 37°C 1 mM IPTG, 3h at 37°C 
Cas3 with N-terminal MBP-tag LB 37°C -18°C 1 mM IPTG, overnight at 18°C 
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Cas3 with N-terminal MBP-tag NZA 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas3 with C-terminal 6xHis-tag LB 37°C 1 mM IPTG, 3h at 37°C 
Cas3 with C-terminal 6xHis-tag NZA 37°C 1 mM IPTG, 3h at 37°C 
Cas3 with C-terminal 6xHis-tag LB 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas3 with C-terminal 6xHis-tag NZA 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas3 with C-terminal cysteine 
protease domain (CPD)-tag 
NZA 37°C 1 mM IPTG, 3h at 37°C 
Cas3 with C-terminal CPD-tag NZA 37°C -18°C 1 mM IPTG, overnight at 18°C 
 
 
Figure 2.10: ssDNA nuclease activity of Cas3. (A) 6% SDS-PAGE of SUMO-Cas3 
after Ni-NTA purification. SUMO-Cas3 co-purified with low molecular weight 
contaminant proteins. (B) Increasing concentrations (250 nM and 500 nM) of 
recombinant SUMO-Cas3 were incubated with 50 nM of 5′-γ-[32P]-ATP labeled 20 nt 
ssDNA in the presence of 10 mM Mg2+ or Mn2+. The cleavage products were 
separated by 20% UREA-PAGE and visualized via phosphorimaging. 
 
2.5.2 Characterization of recombinant Cas1821 as a helical Cascade 
backbone protein 
The absence of observable crRNAs in the Δcas1821 and Δcas1822 strains 
suggests that the encoded Cas proteins are required for maintaining a stable crRNA 
pool in the cell. Thus, these two proteins Cas1821 and Cas1822 could fulfill the roles 
of Cas7 and Cas5 proteins even though sequence similarity calculations did not 
indicate them as members of these Cas protein families (35). Hence, recombinant S. 
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putrefaciens CN-32 Cas1821 and Cas1822 proteins were individually produced in E. 
coli.  
Soluble recombinant Cas1821 was produced as a SUMO-tag fusion 
construct. The SUMO-Cas1821 was purified via Ni-NTA chromatography and co-
eluted with bound nucleic acid contaminants. Therefore, a high-salt washing step 
with a buffer including 1 M NaCl was added before protein elution from the Ni-NTA 
column, and a second cation exchange chromatography step was included in the 
purification protocol. Before cation exchange chromatography, SUMO-Cas1821 was 
treated with SUMO-protease to remove the tag. This procedure yielded Cas1821 
with a purity of >95 % and without nucleic acid contaminants. Gel-elution 
chromatography of Cas1821 revealed a ~35 kDa monomer (Fig. 2.11C). 
Electrophoretic mobility shift assays of Cas1821 with radiolabeled crRNA transcripts 
revealed a slow migrating band indicating the crRNA-binding potential of Cas1821 
(Fig. 2.11A). This band disappeared upon addition of 1 µg of competitor yeast RNA, 
suggesting a non-specific interaction. This behavior is in agreement with the 
observed non-specific binding of E. coli contaminant RNA. Recombinant Cas1821 
bound to these contaminants eluted near the void volume during gel-elution 
chromatography (Fig. 2.11C). These fractions were visualized by electron 
microscopy and revealed the formation of long helical filament-structures of varying 
length (Fig. 2.11B). These observations suggest that Cas1821 could fulfill the role of 
Cas7, which was shown to form the helical Cascade backbone filament after 
unspecific RNA binding in other CRISPR-Cas subtypes (e.g. type I-A, type I-E) 
(34,93).  
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Figure 2.11: Characterization of the recombinant Cas1821 protein. (A) EMSA 
assays indicate the binding of 5′-γ-[32P]-ATP labeled crRNA by 250 nM Cas1821 
(Lane 2) or 500 nM Cas1821 (Lane 3). Bands were separated by 6% native PAGE. 
The RNA binding is unspecific and outcompeted by yeast total RNA. (B) 
Transmission electron micrographs of negatively stained helical structures formed by 
RNA-bound recombinant Cas1821 (provided by Prof. Dr. Andreas Klingl). (C) Size 
exclusion chromatograms of Cas1821 with and without bound RNA. The elution 
profile of apo-Cas1821 measured at 280 nm (in red) shows a single major peak 
corresponding to a mass of ~35 kDa was observed. When bound to RNA, most of 
the protein was found to elute in the void volume (in black). 
 
2.5.3 Purification of recombinant Cas1822 
The production of recombinant Cas1822 as a SUMO fusion construct or with 
a C-terminal 6x His-tag resulted in the formation of inclusion bodies. Several different 
expression conditions were tested before solubilized Cas1822 was produced as a 
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fusion protein containing a C-terminal cysteine protease domain (CPD)-tag (Table 
2.3). A low concentration of Cas1822 was purified via Ni-NTA chromatography and 
subsequently treated with Inositol-6-phosphate to induce autocatalytic cleavage of 
the CPD-tag. The purity of the obtained Cas1822 was low and could not be improved 
by including additional purification steps (Fig 2.12). Hence, in vitro biochemical 
characterization of the protein was not possible. 
 
Table 2.3: List of expression conditions tested for the production of soluble 
recombinant Cas1822. 
Construct Medium Temperature Induction of protein 
production 
Cas1822 with N-terminal SUMO-tag LB 37°C 1 mM IPTG, 3h at 37°C 
Cas1822 with N-terminal SUMO-tag NZA 37°C 1 mM IPTG, 3h at 37°C 
Cas1822 with N-terminal SUMO-tag LB 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas1822 with N-terminal SUMO-tag NZA 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas1822 with C-terminal 6x His-tag LB 37°C 1 mM IPTG, 3h at 37°C 
Cas1822 with C-terminal 6xHis-tag NZA 37°C 1 mM IPTG, 3h at 37°C 
Cas1822 with C-terminal 6xHis-tag LB 37°C -18°C 1 mM IPTG, overnight at 18°C 
Cas1822 with C-terminal 6xHis-tag NZA 37°C -18°C 1 mM IPTG, overnight at 18°C 
 
 
Figure 2.12: Characterization of recombinant of Cas1822 protein. SDS-PAGE of 
Ni-NTA purified Cas1822-CPD. The eluted fractions contained multiple contaminant 
proteins co-eluting with Cas1822-CPD.  
 
2.6 PAM recognition mechanism 
2.6.1 Identification of host proteins involved in PAM recognition 
The loss of interference activity for target DNA molecules with mutations of 
the PAM sequence suggests that the Type I-F variant Cascade contains a PAM 
recognition mechanism. The absence of a cas gene encoding for the large subunit 
protein suggests that either the other Cas proteins of the Cascade or other host 
proteins perform the PAM recognition function. A potential host protein candidate 
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involved in target recognition by Cascade was not identified by bioinformatic 
approaches. Therefore, potential candidates were identified using co-
immunoprecipitation. Three S. putrefaciens CN-32 strains were constructed that 
produced Cas1821, Cas1822 and Cas6f with an N-terminal 6x His-HA-tag, 
respectively. To determine the effect of the tags on the functionality of the proteins, 
interference activity of the three strains was tested via the conjugation-based assay. 
The relative conjugation efficiency of Cas1822-His-HA and Cas6f-His-HA strains 
suggested a loss of interference activity. In addition, the in vivo crRNA abundance 
was probed in these strains. The addition of a His-HA tag on Cas6f or Cas1822 
resulted in a loss of the crRNA pool in the cell, which is consistent with the loss of 
interference activity in these strains. In contrast, the Cas1821-His-HA strain carried a 
stable crRNA pool and showed interference activity, as its conjugation efficiency was 
comparable to the background ΔH-NS strain (Fig. 2.13). Hence, this strain was used 
to perform Co-IP studies. 
 
 
Figure 2.13: Interference activity of strains producing His-HA-tagged Cas 
proteins. (A) S. putrefaciens CN-32 strains producing His-HA-tagged Cas proteins 
were tested for DNA interference using the conjugation assay (see Fig. 2.7). 
Interference was not observed in Cas1822-His-HA and Cas6f-His-HA strains. 
Northern blot analyses performed with a radiolabeled probe complementary to the 
repeat sequence associated the loss of interference in these strains to the absence 
of a stable crRNA pool.  
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The Cas1821-His-HA S. putrefaciens CN-32 strain produces Cas1821 with an 
N-terminal His-HA-tag. Therefore, purification of this protein using Ni-NTA 
chromatography was performed. The eluted fractions were subjected to SDS-PAGE 
and the presence of His-HA-tagged Cas1821 was detected by western blot analysis 
using anti-His antibodies. The fractions containing His-HA-tagged Cas1821 were 
pooled and incubated with magnetic Dynabeads coupled to anti-HA antibodies. After 
incubation, the beads were thoroughly washed and the bound proteins were eluted 
using SDS loading buffer. Following separation by SDS-PAGE, the eluted proteins 
were identified via mass spectrometry. On comparing the proteins eluting with His-
HA-Cas1821 to the ΔH-NS strain, potential Cas1821 interacting partners could be 
identified. Non-specific binding of S. putrefaciens CN-32 proteins to the beads in 
both the background and Cas1821-His-HA strains was observed (Fig. 2.14). Using 
mass spectrometry, a large list of identified proteins was obtained for the elution 
fraction from the beads for both of the strains (Appendix 3). Specific interaction 
partners of His-HA-Cas1821 could not be observed. 
 
 
Figure 2.14: Co-IP analysis using Cas1821-His-HA S. putrefaciens strain. 
Proteins samples eluted (Lane E) from Dynabeads after performing Co-IP on ΔH-NS 
and Cas1821-His-HA strains were separated via SDS-PAGE. The presence of 
Cas1821-His-HA was detected by western blot analyses using anti-His antibodies. 
The lanes indicate the wash fraction (W), flow-through after applying the sample (FT) 
and the elution fraction. 
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2.6.2 Investigation of DinG participation 
The S. putrefaciens CN-32 CRISPR-Cas system is flanked by a homolog of 
the DinG gene (Sputcn32_1824), an ATP-dependent DNA helicase that was 
predicted to be a functional component of Type I-U CRISPR-Cas systems (35). To 
test if this protein plays a role in DNA interference, a ΔDinG strain was constructed. 
A loss of interference activity for this strain was not observed in the conjugation 
assays, indicating that this DinG homolog does not play a direct role in DNA 
interference and is not a component of subtype I-F variant Cascade (Fig. 2.15). This 
is in agreement with the observation, that this DinG homolog is conserved in S. 
putrefaciens strains without CRISPR-arrays or other CRISPR-Cas subtypes.  
 
 
Figure 2.15: Influence of DinG on DNA interference activity. A deletion strain of 
DinG was generated in S. putrefaciens CN-32 wild-type and ΔH-NS strains and 
tested for interference using the conjugation-based assay (see Fig. 2.7). The 
interference-inactive ΔH-NS,Cas1822 strain served as control. 
 
2.6.3 In vivo characterization of a potential DNA target interaction partner 
The absence of a large subunit suggests that other Cas proteins can 
substitute for its role(s) during DNA target interaction. In S. putrefaciens, Cas6f is 
responsible for crRNA biogenesis and Cas1821 is proposed to form the backbone of 
the Cascade. In contrast, the role of Cas1822 is unclear and it is a potential 
candidate for performing the role of large subunit. Therefore, the effect of mutations 
of conserved arginine residues in Cas1822 on DNA interference was tested. Basic 
residues like arginine stabilize protein-nucleic acid interactions by forming salt 
bridges with the phosphodiester backbone and were thus chosen to be mutated. A 
multiple alignment of Cas1822 proteins revealed conserved arginine residues and a 
potential Asp/Glu motif (Fig. 2.16A). We constructed point mutations of the cas1822 
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gene at the appropriate positions to generate corresponding Ala substitutions in 
Cas1822 in vivo. The Cas1822 variants were tested for interference activity. 
Interference was observed for ΔH-NS/R170A, ΔH-NS/R225A and ΔH-
NS/E86A,D87A strains (Fig. 2.16B). A Northern blot analysis verified the presence of 
mature crRNAs in these strains (Fig. 2.16B). In contrast, the two strains ΔH-
NS/R60A and ΔH-NS/R66A lacked interference activity and stable crRNAs. We 
propose that these arginine residues are required for Cascade formation and crRNA 
protection. Finally, the two strains ΔH-NS/R29A and ΔH-NS/R258A did not show 
interference activity even though a stable crRNA pool was observed in the cell. Thus, 
these arginine residues are involved in either the direct interaction with target DNA or 
with the Cas component that recognizes the PAM motif.  
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A 
 
B 
 
Figure 2.16: In vivo characterization of Cas1822 point-mutants. (A) Multiple 
sequence alignment of Cas1822 from S. putrefaciens CN-32 and its homologs 
identified conserved arginine residues and a partially conserved Asp/Glu motif 
(marked by an asterisk). (B) S. putrefaciens CN-32 strains carrying Cas1822 
proteins with the indicated point mutations were tested for DNA interference using 
the conjugation-based assay (see Fig.2.7). Northern Blot analyses with anti-repeat 
probes revealed the cellular crRNA pool of these strains. 
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2.7 Characterization of the minimal Cascade complex 
2.7.1 Reconstitution of the subtype I-F variant Cascade complex from 
inclusion bodies 
The soluble production of the individual Cas proteins was problematic and 
formation of inclusion bodies was observed for Cas1, Cas3, Cas1822 and Cas6. In a 
recent publication, the reconstitution of an active Type I-A Cascade complex from 
inclusion bodies of six Cas proteins was described (34). Therefore, a similar 
approach for obtaining a reconstituted variant Type I-F Cascade was considered. 
Inclusion bodies of the Cas proteins Cas1, Cas3, Cas1822 and Cas6 were purified 
from E. coli in high purity and solubilized by the addition of the denaturing agent, 
guanidine hydrochloride (Gua-HCl) (Fig. 2.17A). The solubilized inclusion bodies of 
the four Cas proteins and soluble Cas1821 were mixed in small quantities (20 
µg/protein) and added to a large volume of buffer (2 ml) to rapidly dilute the 
concentration of the denaturing agent. The reduction of the denaturing agent results 
in the potential refolding of the denatured proteins into their active form. To 
determine the optimum reconstitution procedure, various buffer conditions and 
temperatures were tested and chosen based on the amount of proteins obtained in 
soluble fraction observed via SDS-PAGE (Fig. 2.17B and Table 2.4). By this 
procedure the best refolding condition was determined to be in a buffer containing 50 
mM TRIS/HCl pH 7.0, 300 mM NaCl, 10 mM MgCl2, 1 mM DTT and 10% glycerol at 
4°C.  
 
A             B 
 
Figure 2.17: In vitro refolding of Cas proteins. (A) SDS-PAGE of the solubilized 
inclusion bodies of the individual Cas proteins from S. putrefaciens. (B) The 
solubilized (S) and precipitated (P) fractions of the tested reconstitution condition 
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were analyzed via SDS-PAGE. To determine the optimum reconstitution procedure 
several different reconstitution conditions were tested (buffer condition listed in Table 
2.4). 
Table 2.4: List of the reconstitution buffer conditions that were tested. 
 Buffer conditions 
1 50 mM MES pH 6.0, 10% glycerol, 300 mM NaCl 
2 50 mM TRIS/HCl pH 7.0, 10% glycerol, 300 mM NaCl 
3 50 mM TRIS/HCl pH 8.0, 10% glycerol, 300 mM NaCl 
4 50 mM MES pH 6.0, 10% glycerol, 300 mM NaCl, 1 mM DTT 
5 50 mM TRIS/HCl pH 7.0, 10% glycerol, 300 mM NaCl, 1 mM DTT 
6 50 mM TRIS/HCl pH 8.0, 10% glycerol, 300 mM NaCl, 1 mM DTT 
7 50 mM MES pH 6.0, 10% glycerol, 300 mM NaCl, 0.03 mM GSSG, 0.03 mM GSH, 1 mM 
EDTA 
8 50 mM TRIS/HCl pH 7.0, 10% glycerol, 300 mM NaCl, 0.03 mM GSSG, 0.03 mM GSH, 1 
mM EDTA 
9 50 mM TRIS/HCl pH 8.0, 10% glycerol, 300 mM NaCl, 0.03 mM GSSG, 0.03 mM GSH, 1 
mM EDTA 
10 50 mM MES pH 6.0, 10% glycerol, 300 mM NaCl, 10 mM MgCl2 
11 50 mM TRIS/HCl pH 7.0, 10% glycerol, 300 mM NaCl, 10 mM MgCl2 
12 50 mM TRIS/HCl pH 8.0, 10% glycerol, 300 mM NaCl, 10 mM MgCl2 
 
An alternative method was used to increase the yield of the reconstituted 
proteins. Inclusion bodies of the proteins were mixed at a higher concentration (300 
µg/protein) in 50 mM TRIS/HCl pH 7.0, 300 mM NaCl, 10 mM MgCl2, 1 mM DTT and 
10% glycerol containing 4M Gua-HCl. Instead of rapidly diluting this mixture, the 
denaturing agent was removed by step-wise dialysis. In this procedure, the 
denatured proteins were first brought to equilibrium with a high denaturant 
concentration. Subsequently, the concentration of the denaturant was decreased 
and brought to equilibrium at a medium concentration. This procedure was continued 
until the equilibrium at a very low concentration of denaturant was achieved. 
Although the refolding efficiency of this procedure is better, the formation of inactive 
or mis-folded proteins and protein aggregates is higher. Therefore, after the refolding 
procedure, the dialyzed mixture was centrifuged to separate the reconstituted 
complex from the precipitated proteins and used for further analyses. Following this 
procedure, Cas3 and Cas1 were found to not be essential for the refolding 
procedure, as omission of these proteins did not affect the efficiency of the refolding 
of the other proteins. Therefore two different combinations of reconstituted proteins 
were obtained, Combi-1, which contained only Cas1821, Cas1822 and Cas6f and 
Combi-2, which contained all five Cas proteins (Fig. 2.18). 
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Figure 2.18: Large-scale reconstitution of Cas proteins. SDS-PAGE of 
solubilized Cas proteins obtained from the large-scale reconstitution procedure. Two 
different combinations of Cas proteins could be reconstituted, Combi-1 contained 
Cas1821, Cas1822 and Cas6f where as Combi-2 contained all 5 Cas proteins. 
 
To verify that the reconstituted proteins were folded correctly, the activity of 
individual proteins was tested. First, the endoribonuclease activity of Cas6 was 
tested. A cleavage product was obtained by incubating a radiolabeled spacer3-
repeat-spacer4 transcript with the reconstituted Combi-1 or Combi-2 complexes. The 
endonuclease activity depended on the presence of the catalytic His29 of Cas6. 
Although the use of the His29Ala Cas6 mutant did not affect the reconstitution 
efficiency, a loss of the ribonuclease activity for Combi-1 was observed (Fig. 2.19A). 
Since Cas1821, Cas1822 and Cas6f were proposed to form the Cascade complex, 
the specificity of Combi-1 towards crRNA was tested. While soluble Cas1821 bound 
crRNA nonspecifically, the interaction between the proteins of Combi-1 and crRNA 
could not be disrupted by the addition of total yeast RNA (Fig. 2.19B). Additionally, 
when subjected to size-exclusion chromatography the reconstituted Combi-1 
revealed a major peak at ~75 kDa corresponding to a dimer of Cas1821 and 
Cas1822 (Fig. 2.20). Since Cas3 was included in Combi-2, the ssDNA nuclease 
activity of the complex was tested and found to cleave ssDNA in a metal-dependent 
manner (Fig. 2.19C).  
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Figure 2.19: Activity of reconstituted Cas proteins (A) The endoribonuclease 
activity of Combi-1 and Combi-2 was tested as these complexes contained 
reconstituted Cas6. 250 nM and 500 nM Combi-1 and Combi-2 were incubated with 
50 nM of 5′ radiolabeled spacer-repeat-spacer RNA transcript at 30 °C for 30 min. 
Both Combi-1 and Combi-2 cleaved the RNA and the cleavage product was 
visualized by phosphorimaging after 20% UREA-PAGE. This activity was specific, as 
the use of the Cas6f H29A mutant during reconstitution abolished the 
endoribonuclease activity. (B) Reconstituted Combi-1 specifically bound to the 
crRNA. A slow migration band could be visualized after 6% non-denaturing PAGE on 
incubating 250 nM and 500 nM Combi-1 with 50 nM of crRNA. This band was not 
lost but reduced when 1µg of yeast RNA was added as competitor. (C) The ssDNA 
nuclease activity of Cas3, which was reconstituted in Combi-2 was tested. 500 nM of 
Combi-2 could cleave 50 nM of ssDNA in the presence of 10 mM Mg2+ ions. Under 
similar condition, Cas3 lacking Combi-1 did not show ssDNA nuclease activity. 
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Figure 2.20: Size-exclusion chromatography of reconstituted Combi-1. Dimers 
of Cas1821 and Cas1822 (Lanes 13 and 14) were observed in the major peak of the 
elution profile from Combi-1. After SDS-PAGE, the second peak was found to 
contain monomers of Cas1821 (Lanes 15 and 16) and Cas6f (Lane 17).  
 
The above experiments suggested that correctly folded and active Cas 
proteins were reconstituted from inclusion bodies. The next aim was to show that the 
reconstituted proteins could recognize and cleave target DNA in an in vitro 
interference assay. Therefore, crRNA4 bound Combi-2 complex was incubated with 
ds-spacer4-DNA target that carried a radiolabel at the 5′ end on one of its strands. 
Since ds-spacer1-DNA is not complementary to crRNA4, it was used as a control for 
the interference assay. Although activity of individual proteins could be observed, 
cleavage of a dsDNA by the reconstituted proteins loaded with crRNA could not be 
observed (data not shown).  
 
2.7.2 Production of recombinant subtype I-F variant Cascade  
(The production of the Type I-F variant Cascade was investigated by MSc. student 
Daniel Gleditzsch under my supervision.) 
Due to the described problems associated with inclusion body refolding, the 
simultaneous production of all Cascade components in E. coli was considered. 
Therefore, two compatible plasmids, one for the production of the Cas proteins 
Cas1821, Cas1822 and Cas6f and one for the production of pre-crRNA were 
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constructed and transformed into E. coli. Only Cas1821 contained an N-terminal 
6xHis-Tag and was used to successfully purify the protein from E. coli. Interestingly, 
co-purifying with Cas1821 were the Cas proteins Cas1822 and Cas6f and a crRNA 
of ~60nt in length. The purified proteins were subjected to size-exclusion 
chromatography and the RNA and protein content of the fractions was analyzed (Fig. 
2.21). A distinct peak revealed the formation of a stable complex with an estimated 
size of approximately 215 kDa. The Cas1821 protein was overrepresented in the 
complex, which supports its role as Cascade backbone. Cas1822 and Cas6f were 
co-purified and are suggested to be the proteins that cap the 3′ hairpin tag (Cas6f) 
and the 8 nt 5′ tag (Cas1822) of the crRNA. Additionally a mature crRNA was 
observed to co-purify in the Cascade containing fractions. Thus confirming that 
Cas6f processed the pre-crRNA transcript in E.coli and loaded the Cascade 
complex. EM pictures of the eluted complex revealed a crescent shaped architecture 
similar to the I-F Cascade observed in P. aeruginosa. In addition, Cas1821-Cas1822 
dimers were detected during size exclusion chromatography. Observation of similar 
dimers in the reconstituted proteins suggests that these units are similar to the Cas5-
Cas7 dimers observed for the type I-A Cascade and involved in the assembly of the 
Cascade complex.  
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Figure 2.21: Reconstitution of a recombinant subtype I-F variant Cascade 
complex. His-tagged Cas1821 co-eluted with Cas1822, Cas6f and mature crRNA 
during gel-elution chromatography (fractions 4 and 5), which verified Cascade 
complex formation. A crescent-shaped structure for the complex was observed via 
TEM (indicated by arrows in the lower panel, provided by Dr. Thomas Heimerl). 
Cas1821 filaments were observed in the void volume (fractions 1 and 2). Dimers of 
Cas1821 and Cas1822 (fraction 8) could be identified. SDS-PAGE (middle) and 
UREA-PAGE (bottom) was used to separate the protein and RNA content of the 
fraction indicated in the gel-elution chromatogram (top). 
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3 Discussion 
3.1 The minimal Type I-F variant CRISPR-Cas system is active  
Shewanella putrefaciens CN-32 contains a minimal Type I-F variant CRISPR-
Cas system that encodes a single CRISPR array with 81 spacers and five cas 
genes. Bioinfomatic analyses of this CRISPR-Cas system highlighted features that 
were shared with the Type I-F system. Only three of the five encoded Cas proteins 
have homologs in other Type I-F CRISPR-Cas systems: Cas1 (Sputcn32_1819), 
Cas3 (Sputcn32_1820) and Cas6f (Sputcn32_1820). The two additional protein 
Cas1821 (Sputcn32_1821) and Cas1822 (Sputcn32_1822) shared no detectable 
homology with other known Cas protein families. Accordingly, phylogenetic analyses 
with Cas7 and Cas5 protein families grouped these proteins and its homologs into a 
separate cluster. However, these analyses revealed an evolutionary relationship 
between Cas1821 and the Type I-F Cas7 protein family (Appendix 1). The repeat 
sequence of the S. putrefaciens CRISPR array is pseudo-palindromic and predicted 
to form a stem-loop structure, which was also observed for other Type I-F systems 
(26,58). However, the investigated S. putrefaciens CRISPR-Cas system displays 
significant differences to the standard Type I-F cas gene operon organization. First, 
the three essential Cascade subunits of the Type I-F system (Csy1-3) are absent. 
Instead, the two hypothetical proteins Cas1821 and Cas1822 are present. Second, a 
gene encoding the large subunit protein that is necessary for target DNA binding as 
well as PAM recognition could not be identified in the variant system. Nevertheless, 
the system was shown to be active in vivo. RNA-Seq analyses of isolated small 
RNAs identified all 81 crRNAs from the CRISPR array. The mature crRNAs contain 
the standard 8 nt 5′ repeat tag and an untrimmed 3′ repeat tag with a possible stable 
hairpin structure. The identified Cas6f enzyme processed pre-crRNA transcripts in in 
vitro cleavage assays. Bioinformatic analyses identified this protein as a Cas6f 
variant. In addition to sharing 37% identity with Cas6f from Pseudomonas 
aeruginosa, a conserved histidine at position 29 was identified and found to be 
essential for the endonuclease activity (59). The P. aeruginosa Cas6f was shown to 
remain associated with the hairpin at the 3′ end of the crRNA after cleavage 
(26,43,59). This observation was also reported for Cas6e and Cas5d from 
Escherichia coli and Bacillus halodurans (50,52,94). A similar association of S. 
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putrefaciens Cas6f with the crRNAs could also explain the absence of trimming at 
the 3′ terminal.  
The Type I-F variant CRISPR-Cas system exhibited specific targeting of 
plasmid DNA. Using a conjugation-based in vivo interference assay, the targeting of 
a plasmid carrying a PAM sequence and protospacer was observed. The targeting 
ability of the system depended on cas3, cas1821 and cas1822, as the DNA 
interference activity was abolished in the corresponding deletion strains. The 
absence of interference activity in cas1821 and cas1822 deletion strains 
corresponded with the loss of an observable cellular crRNA pool. Analyses of E. coli 
and Haloferax volcanii Cascade structures showed that Cas5 and Cas7 proteins are 
essential for crRNA maintenance and stability (95,96). Thus, Cas1821 and Cas1822 
could potentially fulfill the roles of these two proteins. The non-specific RNA binding 
of Cas1821 led to the formation of oligomeric structures that could be visualized as 
helical filaments using electron microscopy. The formation of helical filaments was 
previously reported for Cas7 from Thermoproteus tenax, a sub-complex of Cas7 and 
Cas5a subunits from Sulfolobus solfataricus and for Type I-E Cascade in E. coli 
(34,38,93). Thus, it was concluded that Cas1821 subunits build the helical backbone 
of the Cascade structures and fulfill the role of Cas7 proteins. Accordingly, a 
recombinant variant Type I-F Cascade could be purified from E. coli, containing 
multiple copies of Cas1821, Cas1822, Cas6f and a mature crRNA. 
The genes encoding small and large subunits proteins are missing in this 
Type I-F variant CRISPR-Cas system. The effect of the loss of these subunits on 
DNA interference was studied using the conjugation assay. It was observed that this 
system targets dsDNA and depends on the presence of a PAM sequence as 
expected for Type I CRISPR-Cas activity (23,97). The PAM sequence was found to 
be GG and mutations in this sequence resulted in the loss of interference activity. 
This PAM sequence is shared with subtype I-F CRISPR-Cas systems. Additionally, 
as observed for other Type I subtypes, mutations in the seed sequence were not 
tolerated and resulted in the loss of the interference activity (41,97). These results 
raised the question of orphan Cas proteins existing in the genomes of organisms 
containing the subtype I-F variant, which could fulfill the function of small and large 
subunits. It should be noted that an apparent small subunit is also missing for 
subtype I-F CRISPR-Cas systems. The subtype I-F variant CRISPR-Cas system 
was identified in nine mesophilic beta- and gamma-proteobacteria: S. putrefaciens 
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(strains CN-32 & 200), O. ureolytica (strain DSM 18253), P. tunicata (strain D2), L. 
pneumophila (strain 2300/99 Alcoy), O. formigenes (strain OXCC13), P. profundum 
(strain SS9), V. cholerae (strain TM 11079-80) and M. nitratireducenticrescens. 
Phylogenetic profiling of these genomes was performed to identify proteins that can 
substitute for the large subunit. This is a bioinformatics technique based on the idea 
that proteins that are functionally related are gained or lost together from genomes 
during evolution. Using S. oneidensis MR1 as an outgroup, the analyses identified 
the five Cas proteins to be conserved with > 95% identity in all identified genomes 
containing this variant Type I-F system. However, no additional Cas proteins could 
be identified that co-evolved with this minimal system. A homolog of a DinG helicase 
was identified downstream of the CRISPR array, which was reported to be part of 
Type I-U CRISPR-Cas systems (35). However, this enzyme is also found in related 
Shewanella strains without CRISPR systems or with different CRISPR-Cas 
subtypes. A deletion of the DinG gene did not abolish the interference activity 
indicating that the encoded protein is not required for subtype I-F variant Cascade 
activity. To date, RNase III and PNPase are the only non-Cas proteins that can be 
involved in conferring CRISPR-Cas based immunity (28,98). Both proteins play a key 
role in crRNA generation and are not involved in DNA interactions. In conclusion, no 
evidence for any additional Cascade components that are not encoded in the 
minimal cas gene operon was observed. 
During interference, the large subunit of E. coli Type I-E Cascade interacts 
with the PAM motif and recruits Cas3 while both, the small and the large subunits 
are involved in the stabilization of the crRNA-target hybrid (38,67). The subtype I-F 
CRISPR-Cas systems lack a small subunit protein. A large subunit (Csy1) is present 
and contains eight predicted alpha helices at the C-terminus and four helices at the 
extreme N- terminus that is speculated to be a domain homologous to the small 
subunit (35). This protein was reported to form a dimer with Csy2 (Cas5) and bind to 
the 5′ end of the crRNA during the assembly of the Type I-F Cascade (62). The 
subtype I-F Cascade consists of Csy1 (large subunit), Csy2 (Cas5), Csy3 (Cas7) 
and Csy4 (Cas6f) and was shown to recognizes the double stranded G-C/G-C PAM 
(99). It is possible that either Cas1822 and/or Cas3 are involved in the recognition of 
the PAM sequence of the target DNA. The mutation of conserved arginine residues 
in Cas1822 influenced DNA interference activity even in the presence of a stable 
cellular crRNA pool. Phylogenetic analyses of Cas5 protein families revealed an 
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evolutionary relationship between Cas1822 and Cas5d (Appendix 2). Cas5d is the 
enzyme responsible for crRNA biogenesis in the Type I-C CRISPR-Cas system and 
was found to interact non-specifically with dsDNA (63). These results hint that 
Cas1822 might harbor additional functions. Alternatively, Cas3 could interact with the 
dsDNA during interference and could provide additional DNA target selectivity. It is 
interesting to note that the subtype I-F and subtype I-F variant Cas3 enzymes 
contain an N-terminal portion that resembles Cas2 (62). Only this region is 
conserved between Cas3 enzymes found in different Shewanella strains, while the 
larger C-terminal portion shows no apparent homology. Thus, novel Cas3 functions 
could be encoded in this part. It should be noted that the Type I-E and I-F Cascade, 
which were purified without Cas3 bind specifically to dsDNA targets that contain the 
type-specific PAM sequence (38,62,99). In both Types, Cas3 recruitment takes place 
after the recognition of a DNA target and requires structural changes in the large 
subunit (67). A recombinant I-F variant Cascade complex containing only Cas1821, 
Cas1822 and Cas6f can be purified with bound crRNA. If this I-F variant Cascade 
employs a DNA targeting mechanism similar to the I-E and I-F Cascade systems, 
wherein Cas3 is recruited after DNA target recognition, it is plausible that Cas1822 
might be responsible for PAM recognition. The production of pure and soluble 
recombinant Cas1822 and Cas3 proteins was not successful and hence in vitro DNA 
binding experiments with the I-F variant Cascade are necessary to decipher the 
molecular details of PAM recognition mechanism in this variant I-F CRISPR-Cas 
system. 
Previous publications on the Type III CRISPR-Cas systems describe in vitro 
assays that show crRNA-guided RNA cleavage and genetic analyses that 
demonstrated DNA targeting (40,100). However, a molecular mechanism that 
explains these different targeting activities is not obvious. In a recent publication, the 
cleavage of target DNA and its transcript during transcription was reported (78). It 
was shown that the cleavage activity was mediated by two independent active sites 
located on different Cas proteins of the Type III crRNP complex. The palm domain of 
Cas10 was shown to cleave only the target DNA strand of a dsDNA target while it is 
transcribed. Self and non-self discrimination was observed based on the 
complementarity of the 5′ repeat tag of the crRNA to the degraded target strand. In 
contrast, an autoimmune detection mechanism was not identified for the RNA target 
cleavage that was carried out by backbone protein Csm3 and not by Cas10. The 
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dependence of the DNA interference activity on the presence of PAM sequence 
eliminates the possibility of a similar target recognition mechanism in the I-F variant 
system. However, it is plausible that the system employs a similar target DNA 
cleavage mechanism. The in vivo assay used to demonstrate the interference 
activity was based on plasmid conjugation. During conjugation only one DNA strand 
of a plasmid is transferred from the donor to the recipient and replicated into circular 
dsDNA in the recipient. Although the Type I-F variant system targets dsDNA, the in 
vivo assay is limited and cannot distinguish between the cleavage of ssDNA or 
dsDNA. Therefore, it is possible that this variant system can only target the ssDNA 
that is formed during the replication or transcription of the plasmid, as observed for 
the Type III system. This question can be addressed by performing in vitro 
interference experiments with the recombinant Type I-F variant Cascade complex. 
 
3.2 crRNA abundance in S. putrefaciens CN-32 
The RNA-Seq analyses indicated highly variable crRNA abundance patterns. 
The general crRNA abundance was lower than found for other subtypes, e.g. 
subtype I-B (M. maripaludis) or subtype I-A (T. tenax) (25,34). Usually, the most 
abundant crRNAs are the ones closest to the promoter in the CRISPR leader regions 
(25,34,101). These crRNAs contain the most recently acquired spacers. The 
variability of crRNA abundance could be explained by the presence of anti-crRNA 
sequences and internal promoters, which were observed in other cases (48). These 
scenarios are not apparent for the S. putrefaciens CRISPR array. It is plausible that 
the Cascade loading efficiency differs for different crRNAs. Additionally, pre-crRNA 
could form internal structures that would influence Cas6f cleavage site availability. 
 
3.3 Regulation of CRISPR-Cas systems  
A possible regulation of the minimal CRISPR-Cas system in S. putrefaciens 
was identified. Studies in E. coli and Salmonella typhii reported the repression of 
transcription of the cas operon by a global transcriptional repressor, the Heat-stable 
Nucleoid Structuring protein (H-NS) (92,102). In both organisms, H-NS bound to the 
upstream and downstream regions of the transcription initiation site of Cse1 
promoter, resulting in a repression of Cascade transcription. The deletion of the H-
Discussion 
 
 
59 
NS gene in S. putrefaciens resulted in a two-fold change in the cas gene transcript 
levels. Accordingly, an increase in interference activity of the ΔH-NS strain compared 
to the wild-type strain was observed. It is interesting to note that complex and 
multilayered regulatory mechanisms are observed for CRISPR-Cas systems of many 
bacteria. For, E. coli and S. typhii, a complex regulatory mechanism of the CRISPR-
Cas system involves H-NS, the global regulator Leucine-responsive Regulatory 
Protein (Lrp) and a global transcriptional activator LeuO (92,102,103). Additionally a 
secondary regulatory mechanism consisting of RcsB and BglJ was reported to 
influence the transcriptional activation of the Cascade operon in E. coli (104). A 
recent publication demonstrated the regulation of both the acquisition and 
interference mechanisms for the Type I-F system by CRP-cAMP and GalM in 
Pectobacterium atrosepticium (105). Regulation of CRISPR-Cas systems is however 
not limited only to bacteria. The CRISPR-associated proteins, Csa3 and Csx1 have 
been found to regulate the CRISPR-Cas systems in archaea (106). These types of 
complex regulatory mechanisms could be essential to guarantee an appropriate 
defense response with precise timing against viral attacks. In some bacteria, 
CRISPR-Cas systems perform additional unconventional functions other than the 
immune response. The production of Cas9 in Campylobacter jejuni lacking CRISPR 
loci has been demonstrated to increase virulence (107) whereas in L. pneumophila 
Cas2 is required for the infection of amoebae in a CRISPR-independent manner 
(108). In P. aeruginosa and Myxococcus xanthus, the corresponding CRISPR-Cas 
systems are involved in the inhibition of biofilm formation and in exopolysaccharide 
production, respectively (109,110). Although the exact mechanisms behind these 
additional functions are not always clear, they are driven by both environmental (in 
case of virulence, cell morphology) and cytoplasmic (in case of gene regulation) 
stimuli. Therefore, the understanding of these sophisticated regulatory mechanisms 
and stimuli should provide insights into the evolution and maintenance of CRISPR-
Cas systems in prokaryotic genomes. In S. putrefaciens CN-32, genes encoding the 
small and the large subunit proteins could not be identified. For the other Type I 
CRISPR-Cas systems, these proteins play a crucial role during DNA interference 
and are responsible for the target DNA recognition and the stabilization of crRNA-
DNA hybrid (34,38,39,66,67,111,112). The absence of these proteins in S. 
putrefaciens CN-32 may reduce the specificity of the DNA targeting ability of the 
system and could result in off-target cleavage events. Therefore, in addition to 
Discussion 
 
 
60 
triggering a precisely timed immune response, regulation of S. putrefaciens CN-32 
CRISPR-Cas system could be necessary to avoid toxicity from off-target cleavage 
events.  
 
3.4 Assembly of the Cascade complex  
In Cascade complexes of the Type I-C, I-E and I-F CRISPR-Cas systems, the 
corresponding Cas6 enzymes also remain associated with the 3′ hairpin after crRNA 
generation. The stable association of Cas6 to the 3′ hairpin of the crRNA is 
suggested to serve as the starting point of Cascade assembly (51). However, the 
order of the Cascade backbone assembly is unclear. It is not known if Cas7 
oligomerization begins or terminates at one of the two termini of the crRNA. Recent 
publications indicate that the E. coli and H. volcanii CRISPR-Cas systems can target 
DNA with crRNAs generated in a Cas6-independent manner (113,114). These 
reports, together with observation that the removal of the 3′ repeat handle has no 
effect on the target recognition and R-loop formation in vitro, suggests that Cascade 
assembly might initiate at 5′ end of the crRNA (115). Dimers of Cas7 and Cas5a 
were observed in the Type I-A system from S. solfataricus and suggested to form the 
initial building blocks of Cascade (93). The identification of Cas1821 and Cas1822 
dimers during the purification and reconstitution of recombinant S. putrefaciens 
Cascade supports this hypothesis. The recombinant S. putrefaciens Cascade 
contains Cas1822, Cas6f, multiple copies of Cas1821 and a crRNA. The multiple 
copies of Cas1821 are proposed to form the backbone of Cascade and bind to the 
crRNA, while Cas1822 and Cas6f might protect the 5′ and 3′ end of the crRNA 
respectively. The recombinant I-F variant Cascade complex can be produced in E. 
coli using two compatible plasmids, one for the production of the Cas proteins and 
one for production of pre-crRNA. This can serve as the starting point for designing 
experiments that address the question of the order of Cascade assembly. Second, 
the constraints placed by the crRNA on the structure of Cascade can be tested. 
Finally, structural studies using X-ray crystallography techniques could be carried out 
for the Type I-F variant complex. 
The visualization of the Type I-F variant minimal Cascade using electron 
microscopy revealed a crescent shaped architecture of the complex. The general 
shape is conserved in crRNP complexes from both Type I and Type III CRISPR-Cas 
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systems even though the constituting Cas proteins, as well as the nucleic acid 
targets vary significantly (64,68). This universal layout is a result of the binding of 
crRNAs by proteins of the Cas7 superfamily (e.g., Cas7, Cmr4, and Csm3). In all of 
these crRNP complexes, oligomerization of Cas7 results in a crRNA that is kinked at 
six-nucleotide intervals caused by the interaction of the thumb domain of one 
backbone subunit with the palm domain of the adjacent subunit (38,39,116). During 
the hybridization of the crRNA with a complementary target, five nucleotides of each 
interval base pair with the target, while the thumb domain of Cas7 blocks the base 
pairing of the sixth nucleotide. This results in the kinking of the target backbone and, 
in Type I systems, the destabilization of dsDNA and the initiation of R-loop formation 
(38,39). A similar dsDNA binding mechanism is probably observed in the Type I-F 
variant system. However, further structural and biochemical studies of the minimal 
Cascade are necessary to confirm this hypothesis. Although the targeting 
mechanism of the Type I and Type III systems are distinct, the structural and 
functional similarities observed for the surveillance complexes of these systems 
suggest an evolutionary connection (35,117). It was proposed that the modern 
CRISPR-Cas systems evolved form an ancestral Type III-A like system (17,35). This 
system probably consisted of six or seven genes including the two universal Cas 
proteins, Cas1 and Cas2, (for spacer acquisition) along with four or five additional 
proteins (crRNP complex) involved in crRNA processing and interference. The 
crRNP complex would include the large subunit (Cas10/Cas8), the small subunit and 
two or three RNA binding backbone proteins. The evolution of Type I systems might 
be a result of the inactivation of the Cas10 palm domain, which led to the evolution of 
Cas8 and the acquisition of Cas3 helicase. In contrast to the Type III crRNP 
functionality, the acquisition of Cas3 helicase equipped Type I systems to unwind 
dsDNA without depending on the host RNA polymerase activity. This event probably 
triggered the switch from the targeting of both DNA and RNA, as observed in Type III 
systems, to the exclusive targeting of dsDNA and the evolution of PAM sequences 
as autoimmune detection mechanisms. Compared to the Type I and Type III 
systems, the Type II CRISPR-Cas systems are distinct. This system is considered to 
have evolved recently, based on the presence of two unrelated nuclease domains 
within a single Cas9 protein that performs the function of both, CRISPR processing 
and interference. Nevertheless, experimental data on Cas9 activity indicates 
functional similarity to the crRNP complexes of Type I and Type III systems (46). The 
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loss of large and small subunits in the minimal Type I-F variant system might 
coincide with the evolution of specialized minimal type I Cascade systems that still 
rely on PAM motif recognition for DNA target specificity.  
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4  Material and methods 
4.1 Chemicals, enzymes and consumables  
Table 1: List of chemicals, enzymes, kits and consumable used in this study. 
Chemicals Company 
Acrylamide, N,N-methylenebisacrylamide Roth GmbH, Karlsruhe 
Alkaline phosphatase, calf intestinal (HC) Fermentas GmbH, St. Leon-Rot 
Kanamycin, ampicillin, spectinomycin, 
chloramphenicol 
Sigma-Aldrich, Taufkirchen ; Roth GmbH, 
Karlsruhe 
Bradford Reagent  BioRad, München  
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen  
Coomassie brilliant blue R and G SERVA GmbH, Heidelberg  
Dialysis tubes Roth GmbH, Karlsruhe; Serva GmbH, Heidelberg  
Diethyl pyrocarbonate (DEPC)  AppliChem GmbH, Darmstadt  
DNA ladder Mix New England Biolabs, Frankfurt 
DNA ladder, ultra low range New England Biolabs, Frankfurt 
Phusion DNA polymerase Fermentas GmbH, St. Leon-Rot 
Taq DNA polymerase New England Biolabs, Frankfurt 
DNase I  Sigma-Aldrich, Taufkirchen  
dNTP Mix  New England Biolabs, Frankfurt 
Isopropyl-ß-thiogalactopyranoside (IPTG) Roth GmbH, Karlsruhe 
mirvanaTM miRNA Isolation Kit  Applied Biosystems, Darmstadt 
Ni-NTA agarose  Qiagen, Hilden ; Life Technologies, Karlsruhe 
Oligonucleotides  Eurofins MWG operon, Ebersberg 
Color prestained protein standard, 11-245 kDa  New England Biolabs, Frankfurt 
Color prestained protein standard, 10-250 kDa New England Biolabs, Frankfurt 
Roti®-Nylon plus, nylon membrane  Roth GmbH, Karlsruhe 
Qiagen Plasmid-Kit, QIAquick Gel Extraction Kit, 
QIAquick Nucleotide Removal Kit, QIAquick PCR 
Purification Kit 
Qiagen, Hilden 
Restriction endonucleases New England Biolabs, Frankfurt 
Reverse transcriptase New England Biolabs, Frankfurt 
RNA ladder, high range New England Biolabs, Frankfurt 
RNase-ExitusPlusTM AppliChem GmbH, Darmstadt 
Sodium dodecyl sulfate  SERVA GmbH, Heidelberg 
T4 DNA Ligase New England Biolabs, Frankfurt 
T7 RNA Polymerase  New England Biolabs, Frankfurt 
TRIzol Reagent  Life Technologies, Karlsruhe 
Whatman GB 004, 3MM Schleicher & Schuell GmbH, Dassel 
T4 polynucleotide kinase 
New England Biolabs, Frankfurt; Life 
technologies, Karlsruhe 
4-(2-aminoethyl)benzenesulfonylfluoride 
hydrochloride 
Sigma-Aldrich, Taufkirchen 
Protease cocktail Roth GmbH, Karlsruhe 
Lysozyme Sigma-Aldrich, Taufkirchen 
iQ SYBR Green Supermix Kit Bio-Rad, München 
Materials and methods 
 
 
64 
The chemicals and consumables that are not listed above were purchased 
from AppliChem GmbH (Darmstadt), BioRad Laboratories GmbH (München), 
Biozym GmbH (Hessisch-Oldendorf), Difco Laboratories GmbH (Augsburg), 
Invitrogen (Karlsruhe), Merck KGaA (Darmstadt), Roche GmbH (Mannheim), Roth 
GmbH  (Karlsruhe), VWR International (Darmstadt), SERVA GmbH (Heidelberg) and 
Sigma-Aldrich Co. (Deisenhofen). 
 
4.2 Strains and culture conditions 
4.2.1 Strains used 
Table 2: List of bacterial strains used in this study. 
Strain Description Source 
Shewanella putrefaciens  
CN-32, ATCC BAA-453D-5  
 Fredrickson et al., 
1998 (118) 
 
Escherichia coli DH5α  
FhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ) M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
Novagen 
 
Escherichia coli DH5α λpir 
sup E44, ΔlacU169 (ΦlacZΔM15), recA1, 
endA1, hsdR17, thi-1, gyrA96, relA1, λpir 
phage lysogen 
Miller et al., 1988 
(119) 
 
Escherichia coli WM3064 
thrB1004 pro thi rpsL hsdS lacZΔM15 RP4-
1360 Δ(araBAD)567 ΔdapA1341::[erm pir] 
W. Metcalf, 
University of Illinois 
Escherichia coli BL21(DE3) 
pLsyS 
F-ompT hsdSB(rB- mB-) gal dcm (DE3) pLysS 
(SpecR) Novagen 
 
4.2.2  S. putrefaciens CN-32 strains  
Table 3: List of S. putrefaciens CN-32 strains generated during this study. 
Strain Description Source 
Δcas1 ΔSputcn32_1819 AG Thormann 
Δcas2-cas3 ΔSputcn32_1820 AG Thormann 
Δ1821 ΔSputcn32_1821 AG Thormann 
Δ1822 ΔSputcn32_1822 AG Thormann 
ΔH-NS ΔSputcn32_2512 This work 
ΔDinG Truncation in Sputcn32_1824 This work 
ΔH-NS, cas2-cas3 Δ2512, Δcas1820 This work 
ΔH-NS, 1822 Δ2512, Δcas1822 This work 
ΔH-NS, DinG Δ2512, truncation of Sputcn32_1824 This work 
ΔH-NS, 1822(R29A) Δ2512, R29A mutation in Cas1822 This work 
ΔH-NS, 1822(R60A) Δ2512, R60A mutation in Cas1822 This work 
ΔH-NS, 1822(R66A) Δ2512, R66A mutation in Cas1822 This work 
ΔH-NS, 1822(R170A) Δ2512, R170A mutation in Cas1822 This work 
ΔH-NS, 1822(R225A) Δ2512, R225A mutation in Cas1822 This work 
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ΔH-NS, 1822(R258A) Δ2512, R258A mutation in Cas1822 This work 
ΔH-NS, 1822(E86A, D87A) 
Δ2512, E86A and D87A mutations in 
Cas1822 This work 
ΔH-NS, Cas1821-His-HA Δ2512, Cas1821 produced with N-
terminal His-HA tag 
AG Thormann 
ΔH-NS, Cas1822-His-HA Δ2512, Cas1822 produced with N-
terminal His-HA tag 
AG Thormann 
ΔH-NS, Cas6f-His-HA 
Δ2512, Cas6 produced with N-terminal 
His-HA tag AG Thormann 
 
4.2.3 Culture condition for S. putrefaciens CN-32 
Aerobic growth of S. putrefaciens CN-32 strains were carried out at 30°C 
using Lysogeny Broth (LB) media (1% bacto-tryptone, 0.5% yeast extract, 1% NaCl 
(w/v), pH 7.0) in Erlenmeyer flask with constant agitation in a rotary shaker (200 rpm) 
or on solid medium plates (LB containing 1.5% (w/v) agar). The medium was 
supplemented with 50 mg/ml kanamycin (kan), 300 µM 2,6-diaminopimelic acid 
(DAP) or 10 % sucrose (v/v) when required. 
 
4.2.4 Culture conditions for E. coli 
Aerobic growth of E. coli was carried out at 37°C using LB medium or NZA 
medium (1% NZ-Amine, 0.5% yeast extract, 1% NaCl (w/v), pH 7.0) in Erlenmeyer 
flasks accompanied by shaking in a rotary shaker or on solid LB media plates. 
Growth was monitored at OD600 after inoculating the media supplemented with 
appropriate antibiotics with an overnight pre-culture (2% v/v). Protein production was 
induced by the addition of IPTG (1 mM final concentration) when OD600 of 0.6-0.8 
was achieved. Cells were harvested by centrifugation (4000 rpm, 20 min, 4°C) after 
overnight incubation at 18°C or incubation for 3 h at 37°C and stored at -80°C. E. coli 
BL21(DE3) pLysS strain was used for heterologous production of S. putrefaciens 
CN-32 proteins using the plasmids listed in Table 5. E. coli strains DH5α and DH5α 
λpir were used for cloning and storage of plasmids whereas E. coli WM3064 was 
used during conjugation. 
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4.3 Primers and constructed recombinant vectors 
Table 4: Plasmids used in this study. 
Vector Resistance Application 
pUC19 AmpR In vitro transcription 
pBRR1MCS2 KanR Cloning 
pET-20b AmpR Protein production 
pRSF-Duet KanR Protein production 
pETM-43 KanR Protein production 
pEC-His-A AmpR Protein production 
pCPD AmpR Protein production 
pCDF-Duet SpecR Protein production 
pNPTS138-R6KT KanR In-frame insertion or gene deletion 
 
Table 5: List of recombinant vectors constructed in this study. 
Plasmid + Insert Description 
pET-20b + cas1 Cas1 with a 6x His-tag (C-terminal) 
pET-20b + cas3 Cas3 with a 6x His-tag (C-terminal) 
pET-20b + cas1821 Cas1821 with a 6x His-tag (C-terminal) 
pET-20b + cas1822 Cas1822 with a 6x His-tag (C-terminal) 
pET-20b + cas6 Cas6f with a 6x His-tag (C-terminal) 
PETM-43 + cas3 Cas3 with a 6x His-maltose binding protein-tag (N-terminal) 
pEC-His-A + cas3 Cas3 with a 6x His-SUMO-tag (N-terminal) 
pCPD + cas3 Cas3 with a cysteine protease domain (CPD)-6x His- tag (C-terminal) 
pEC-His-A + cas1821 Cas1821 with a 6x His-SUMO-tag (N-terminal) 
pET20b + cas1821 (no tag) Cas1821 without a tag 
pEC-His-A + cas1822 Cas1822 with a 6x His-SUMO-tag (N-terminal) 
pCPD + cas1822 Cas1822 with a CPD 6x His- tag (C-terminal) 
pET20b + cas1822 (no tag) Cas1822 without a tag 
pCDF-Duet + cas1821, cas1822 Cas1822 with a 6x His-tag (N-terminal) and Cas1821 without 
a tag 
pEC-His-A + cas3 (H156A) Cas3 with a 6x His-SUMO-tag (N-terminal) carrying a H156A 
mutation 
pCPD + cas3 (H156A) Cas3 with a CPD-6x His- tag (C-terminal) carrying a H156A mutation 
pCPD + cas3 (D157A) Cas3 with a CPD-6x His- tag (C-terminal) carrying a D157A mutation 
pET-20b + cas6 (H29A) Cas6f with a 6x His-tag (C-terminal) carrying a H29A mutation 
pRSF-Duet 567 pRSFduet1 carrying cas1821, cas1822 and cas6 as an 
operon with an N-terminal 6x His-tag on Cas1821 
pUC19 +spacer3-repeat-spacer4 pUC19 carrying a spacer3-repeat-spacer4 fragment 
pUC19 + crRNA4 pUC19 carrying a repeat-spacer4-repeat (partial) fragment 
pUC19 + hammerhead crRNA1 pUC19 carrying a hammerhead ribozyme and repeat-spacer1-repeat (partial) fragment 
pUC19 + hammerhead crRNA4 pUC19 carrying a hammerhead ribozyme and repeat-spacer4-repeat (partial) fragment 
pNPTS138-R6KT-ΔH-NS H-NS deletion fragment in pNPTS138-R6KT 
pNPTS138-R6KT-ΔDinG DinG deletion fragment in pNPTS138-R6KT 
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pNPTS138-R6KT-cas1822 
cas1822 and 500 bp upstream and downstream fragment 
(3011 bp) in pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R29A 
Fragment carrying the R29A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R60A 
Fragment carrying the R60A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R66A 
Fragment carrying the R66A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R170A 
Fragment carrying the R170A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R225A 
Fragment carrying the R225A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-R258A 
Fragment carrying the R258A mutation of cas1822 in 
pNPTS138-R6KT 
pNPTS138-R6KT- cas1822-
E86A,D87A 
Fragment carrying the E86A and D87A mutations of cas1822 
in pNPTS138-R6KT 
 
pBBR1MCS2-sp1-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 1 with 
the ´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp3-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 3 with 
the ´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp13-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 the 
´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp15-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 15 
with the ´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp20-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 20 
with the ´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp34-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 34 
with the ´GG´ PAM on the 3´end of the target strand 
pBBR1MCS2-sp13rev-GG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 in 
the opposite orientation than before 
pBBR1MCS2-sp13-AA 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 
with the ´AA´PAM on the 3´end of the target strand 
pBBR1MCS2-sp13-GA 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 
with the ´GA´PAM on the 3´end of the target strand 
pBBR1MCS2-sp13-AG 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 
with the ´AG´PAM on the 3´end of the target strand 
pBBR1MCS2-sp13-CC 
pBBR1MCS2 containing S. putrefaciens CN-32 spacer 13 
with the ´CC´PAM on the 3´end of the target strand 
pBBR1MCS2-sp13-polyA 
pBBR1MCS2 containing poly A as the first 10 nucleotides of  
S. putrefaciens CN-32 spacer 13 
 
Table 6: List of primers used in this study. 
Primers Sequence 5′à3′    
Cloning of cas1 into pET-20b  
Forward GGTACAGAACATATGATGGTGACATTC 
Reverse CATAAGCTTTTCCTCATCTTCAGTGG 
Cloning of cas3 into pET-20b  
Forward GTACAGAAGCTCATATGATGGTGACATTCA 
Reverse TACTTTTTGCATCTCGAGTTCCTCATCTTC 
Cloning of cas1821 into pET-20b  
Forward AGATGAGGAATAACATATGCAAAAAGTAAC 
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Reverse TTCTTGCAACCTCGAGTTTTGCAT 
Cloning of cas1822 into pET-20b  
Forward GCAAAATAGGAGGTCATATGAAAATAATC 
Reverse CATCATTGGTCGACAAGCTTAATGTTT 
Cloning of cas6 into pET-20b  
Forward TTTAGGACATATGATGAACTCATATATTGATA 
Reverse AAGAACAAAAATAAACTCGAGAAACCAAGG 
Cloning of cas3 into pETM-43  
Forward AGAATTCATGATGGTGACATTCATCAGTCAGTGCGAG 
Reverse GCTCGAGTTCCTCATCTTCAGTGGTTTGATTAATT 
Cloning of cas3 into pEC-His-A  
Forward ACCAGGAACAAACCGGCGGCCGCTCGATGATGGTGACA
TTCATCAGTCAGTGCGAG 
Reverse GCAAAGCACCGGCCTCGTTATTATTCCTCATCTTCAG 
Cloning of cas3 into pCPD  
Forward GTACAGAAGCTCATATGATGGTGACATTCA 
Reverse TACTTTTTGCATCTCGAGTTCCTCATCTTC 
Cloning of cas1821 into pEC-His-A  
Forward ACCAGGAACAAACCGGCGGCCGCTCGATGCAAAAAGTA
ACGGGAATTAAAAGTGT 
Reverse 
 
GCAAAGCACCGGCCTCGTTACTATTTTGCATAAAAATACT
GTGCAAATGGC 
Cloning of cas1821 into pET-20b 
without a tag   
Forward ATCATATGCAAAAAGTAACGGGAATTAAAA 
Reverse TTCTCGAGCTATTTTGCATAAAAATACTGTGC 
Cloning of cas1822 into pEC-His-A  
Forward ACCAGGAACAAACCGGCGGCCGCTCGATGAAAATAATC
ATAGAATATGACTCTTGCTGGCG 
Reverse GCAAAGCACCGGCCTCGTTACTAAAGCTTAATGTTTGAT
ACATAGGCCAG 
Cloning of cas1822 into pCPD  
Forward GCAAAATAGGAGGTCATATGAAAATAATC 
Reverse CATCATTGGTCGACAAGCTTAATGTTT 
Cloning of cas1822 into pET-20b 
without a tag   
Forward CCCATATGAAAATAATCATAGAATATGACTC 
Reverse TTCTCGAGCTAAAGCTTAATGTTTGATACATAGG 
Cloning of cas1821 and cas1822 into 
pCDF-duet 
 
1822-Forward GCAAAATAGGAGAATTCATGAAAATAATC 
1822-Reverse CATCATTGGTCGACAAGCTTAATGTTT 
1821-Forward AGATGAGGAATAACATATGCAAAAAGTAAC 
1821-Reverse TTCTTGCAACCTCGAGTTTTGCAT 
Cloning of cas1821, cas1822 and 
cas6 as an operon into pRSF-duet 	  
Forward AGCGGATCCGATGCAAAAAGTAACGGGAATTAAAAGTGT
T	  
Reverse GATTGCGGCCGCTTAAAACCAAGGTACTGTAGCGGTTTT
GCT	  
Cloning of sp3-rep-sp4  
Forward GGATCCTAATACGACTCACTATAGGGAGATATTGAGTTTG
CATCAAGCA 
Reverse AAGCTTGGTTATAGGTTTGCGCGTCTTGCTGGGCGATA 
In frame deletion of H-NS  
H-NS KO up fw CGAATTCATACTGACAACAACCACTTCGGTA 
H-NS KO up OL rv CCTTTTACTGCGAGTTTGTATGGAATCTATTTTCGTCCCA
CTTTAATTTTTAAT 
H-NS KO dwn OL fw ATTAAAAATTAAAGTGGGACGAAAATAGATTCCATACAAA
CTCGCAGTAAAAGG 
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H-NS KO dwn rv GGTTGGATCCGGTAAAGGGATCGATAAATCCGGG 
H-NS check fw TGCAGTACGTAGCTGTTCTTGTA 
H-NS check rv TAATATCATAAACAGGGCGTGTCAGT 
In frame truncation of DinG  
DinG KO up fw GCGGAATTCTATCTTAAATCAGCATAATGCTTCGAACTC 
DinG KO up OL rv 
TTGTCCGCCAATATTATTAACAAGATGTTTTCTTGCAGATT
TTTACTGCCCGTACTAATG 
DinG KO dwn OL fw 
CATTAGTACGGGCAGTAAAAATCTGCAAGAAAACATCTTG
TTAATAATATTGGCGGACAA 
DinG KO dwn rv CGCGGATCCACCCAACAATAAAGAAGGAAAATAATATGC 
DinG check fw GTAAATCTGAATAGCCGCACACGCGGCTTTAA 
DinG check rv ATACCTACATCATATTCACACAACATGCGC 
Construction of in vivo His-HA 
tagged Cas1821  
1821 up BamHI fw CGGATCCGAACACTTATACCTTAGCTGTTCC 
1821 up OL rv 
GCATTATCGATCAGATGGTGATGGTGATGGTGCATGATT
TATTCCTCATCTTCAGTGG 
1821 up OL fw 
CCATCTGATCGATAATGCATACCCATACGATGTTCCAGAT
TACGCTCAAAAAGTAACGGGAATTAAAAGTG 
1821 dwn EcoRI rv CGAATTCGCGTTCTAATGTTTCAGCAACC 
Construction of in vivo His-HA 
tagged Cas1822  
1822 up BamHI fw CGGATCCATTGCATTCGCCATCATTTATTTCG 
1822 up OL rv 
GCATTATCGATCAGATGGTGATGGTGATGGTGCATGCAA
CCTCCTATTTTGCATAAAAATAC 
1822 up OL fw 
CCATCTGATCGATAATGCATACCCATACGATGTTCCAGAT
TACGCTAAAATAATCATAGAATATGACTCTTGCTG 
1822 dwn EcoRI rv CGAATTCGTCCCGTTGTATATCGGTCC 
Construction of in vivo His-HA 
tagged Cas6  
Cas6 up BamHI fw CGGATCCTTATAGATAAGCCGCAGTTGACC 
Cas6 up OL rv 
GCATTATCGATCAGATGGTGATGGTGATGGTGCATGCAT
CATTGCTCCTAAAGCTTAATG 
Cas6 up OL fw 
CCATCTGATCGATAATGCATACCCATACGATGTTCCAGAT
TACGCTAACTCATATATTGATATACGGCTG 
Cas6 dwn EcoRI rv CGAATTCTGGTCGCGCAATTTATGATTTGG 
In vivo mutations in Cas1822  
1822 fw GAGGAATTCGGAGCAAGAGATAGTACATCATTTTTTTCA 
1822 rv AGCGGATCCTGAGCTTGAATGTCGCTAAACTCAAAGAAT 
R29A fw CATTGAGCCTAAAAATTCGGCGCCTTTTTTCGGTACAGGT 
R29A rv 
ACCTGTACCGAAAAAAGGCGCCGAATTTTTAGGCTCAAT
G 
R60A fw 
TTCGTTGGTCGCCAATTAAAGCATTTAGTACTCCCATTAC
GG 
R60A rv 
CCGTAATGGGAGTACTAAATGCTTTAATTGGCGACCAAC
GAA 
R66A fw CGCGCCTGATAAAGCTTTGCTTGGTCGCCAATTAAACG 
R66A rv CGTTTAATTGGCGACCAAGCAAAGCTTTATCAGGCGCG 
R170A fw 
GATTAAGGCTCTCCAAGGCATTGATAATACTTAACGGGTT
TAACTCAATA 
R170A rv 
TATTGAGTTAAACCCGTTAAGTATTATCAATGCCTTGGAG
AGCCTTAATC 
R225A fw 
TATTAAAGCTAGTTTCTAAGGCGGCAAGCTGAAGGTAAA
GCG 
R225A rv 
CGCTTTACCTTCAGCTTGCCGCCTTAGAAACTAGCTTTAA
TA 
R258A fw 
TTTTTTGGGTCCCGTTGTATATGCGTCCATGAAGTCTTTT
TTAGTG 
R2258A rv 
CACTAAAAAAGACTTCATGGACGCATATACAACGGGACC
CAAAAAA 
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E86A D87A fw 
GCTTATCTATAAAGCTGACTTTAGCTGCCAGTGCTTCGAA
GTAATAAGCG 
E86A D87A rv 
CGCTTATTACTTCGAAGCACTGGCAGCTAAAGTCAGCTTT
ATAGATAAGC 
Generation of Cas3 H156A mutant  
Forward CGAATTTTATTGCAGGTTGCTTGGCTGATTTAGGGAAAAT
TGACCCAA 
Reverse TTGGGTCAATTTTCCCTAAATCAGCCAAGCAACCTGCAAT
AAAATTCG 
Generation of Cas3 D157A mutant  
Forward TTGCAGGTTGTTTGCATGCTTTAGGGAAAATTGACCC 
Reverse GGGTCAATTTTCCCTAAAGCATGCAAACAACCTGCAA 
Generation of Cas6 H29A mutant  
Forward GCTGAGCTCAGTAGTAAAGTATTTACTAAATTTGCGAAAG
CGTTAGTGACGCTC 
Reverse GAGCGTCACTAACGCTTTCGCAAATTTAGTAAATACTTTA
CTACTGAGCTCAGC 
Cloning of crRNA4  
 
Forward 
GATCCTAATACGACTCACTATAGGGAGAGTTCACCGCCG
CACAGGCGGCTTAGAAATATCGCCCAGCAAGACGCGCA
AACCTATAACCGTTCACCGCCGCACAGGCGGA 
 
Reverse 
AGCTTCCGCCTGTGCGGCGGTGAACGGTTATAGGTTTGC
GCGTCTTGCTGGGCGATATTTCTAAGCCGCCTGTGCGGC
GGTGAACTCTCCCTATAGTGAGTCGTATTAG 
Cloning of hammerhead crRNA1  
Forward1 GATCCTAATACGACTCACTATAGGGAGATAAGCTGATGA
GTCCGTGAGGACGAAACGGTACCCG 
Forward2 GTACCGTCCTTAGAAATCAACCAAATCATAAATTGCGCGA
CCACATTGGTTCACCGCCGCACAGGCGGCCA 
Reverse1 GACGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCA
GCTTATCTCCCTATAGTGAGTCGTATTAG 
Reverse2 AGCTTGGCCGCCTGTGCGGCGGTGAACCAATGTGGTCG
CGCAATTTATGATTTGGTTGATTTCTAAG 
Cloning of hammerhead crRNA4  
Forward1 GATCCTAATACGACTCACTATAGGGAGATAAGCTGATGA
GTCCGTGAGGACGAAACGGTACCCG 
Forward2 GTACCGTCCTTAGAAATATCGCCCAGCAAGACGCGCAAA
CCTATAACCGTTCACCGCCGCACAGGCGGCCA 
Reverse1 GACGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCA
GCTTATCTCCCTATAGTGAGTCGTATTAG 
Reverse2 AGCTTGGCCGCCTGTGCGGCGGTGAACGGTTATAGGTTT
GCGCGTCTTGCTGGGCGATATTTCTAAG 
Cloning of sp1 with the ´GG´ PAM  
Forward AATTCCCTCAACCAAATCATAAATTGCGCGACCACATTGG 
Reverse GATCCCAATGTGGTCGCGCAATTTATGATTTGGTTGAGG
G 
Cloning of sp3 with the ´GG´ PAM  
Forward AATTCCCTATTGAGTTTGCATCAAGCACGGTATGGCGCT
G 
Reverse GATCCAGCGCCATACCGTGCTTGATGCAAACTCAATAGG
G 
Cloning of sp13 with the ´GG´ PAM  
Forward AATTCCCCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACAGACATAACGGG
G 
Cloning of sp15 with the ´GG´ PAM  
Forward AATTCCCGTTAACAGTTGCTGGCAACGTCTTTTGCACCTG 
Reverse GATCCAGGTGCAAAAGACGTTGCCAGCAACTGTTAACGG
G 
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Cloning of sp20 with the ´GG´ PAM 
Forward AATTCCCGCAGGGACTCGCGCAAAGGCTGGCGTTATGA
GG 
Reverse GATCCCTCATAACGCCAGCCTTTGCGCGAGTCCCTGCGG
G 
Cloning of sp34 with the ´GG´ PAM  
Forward AATTCCCTGTTGGATTTGGCTCTTGGTTCGGCGCTTCGG
G 
Reverse GATCCCCGAAGCGCCGAACCAAGAGCCAAATCCAACAG
GG 
Cloning of sp13 with the ´GG´ PAM 
in reverse  
Forward AATTCTATTGGAAGTTGACAGTGTAACAGACATAACGGG
G 
Reverse GATCCCCCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Cloning of sp13 with the ´AA´ PAM   
Forward AATTCTTCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACAGACATAACGAA
G 
Cloning of sp13 with the ´GA´ PAM   
Forward AATTCTCCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACAGACATAACGGA
G 
Cloning of sp13 with the ´AG´ PAM   
Forward AATTCCTCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACAGACATAACGAG
G 
Cloning of sp13 with the ´CC´ PAM   
Forward AATTCGGCGTTATGTCTGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACAGACATAACGCC
G 
Cloning of polyA containing sp13   
Forward AATTCCCAAAAAAAAAAGTTACACTGTCAACTTCCAATAG 
Reverse GATCCTATTGGAAGTTGACAGTGTAACTTTTTTTTTTGGG 
qPCR primers  
16S-fw GCCTTATCTGTGACGTTACC 
16S-rv GCTTTACGCCCAGTAATTCC 
1819-Cas1-fw AAGACGCCATCGTATTACCC 
1819-Cas1-rv GGTCGGTAAAGGCTTGTAAC 
1820-Cas2,3-fw GGCATAGTGCCAGTGAATAG 
1820-Cas2,3-rv GTGGCTGTAATTGGGTGTTG 
1821-fw GGCGTAGTGAATTGGAATGG 
1821-rv CCGGTCAAGTTTGTGTAGC 
1822-fw TGGCAGTACGGATCAGAATG 
1822-rv GTGAAATCGAGAGCCAACAC 
1823-fw TATACGGCTGAAGCCTGATG 
1823-rv GGCTATTGAGCGTCACTAAC 
Probes for northern blots   
Repeat sequence GTCTTGCTGGGCGATATTTC 
16S control GCTTTACGCCCAGTAATTCC 
In vitro interference assay primers  
Sp1 target 
AAGCTTGAGGCCCCAAGGGGTTATGCTAGCAATGTGGTC
GCGCAATTTATGATTTGGTTGAGGACTCCCTATAGTGAGT
CGTATTAGGATCC 
Sp1 non-target 
GGATCCTAATACGACTCACTATAGGGAGTCCTCAACCAA
ATCATAAATTGCGCGACCACATTGCTAGCATAACCCCTTG
GGGCCTCAAGCTT 
Sp4 target 
AAGCTTGAGGCCCCAAGGGGTTATGCTAGGGTTATAGGT
TTGCGCGTCTTGCTGGGCGATAGGACTCCCTATAGTGAG
TCGTATTAGGATCC 
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Sp4 non-target 
GGATCCTAATACGACTCACTATAGGGAGTCCTATCGCCC
AGCAAGACGCGCAAACCTATAACCCTAGCATAACCCCTT
GGGGCCTCAAGCTT 
 
4.4 Working with RNA 
4.4.1 Treatment of solutions, glassware and equipment  
For protection against RNases, all applied buffers and solutions were treated 
with 0.1% (v/v) diethylpyrocarbonate (DEPC) and autoclaved to remove traces of 
DEPC after an overnight incubation at RT. Non-disposable plastic ware were treated 
with RNase Exitus Plus (AppliChem) whereas pipette tips and reaction tubes were 
autoclaved twice before use. Glassware was heat sterilized by incubation at 210°C 
for at least 2 hours before use. 
 
4.4.2 Isolation of total RNA and small RNA from S. putrefaciens CN-32 
4.4.2.1 Isolation of RNA using isopropanol  
Total RNA from S. putrefaciens CN-32 was extracted using TRIzol reagent 
(Invitrogen), a solution containing phenol and guanidinium isothiocyanate.  Two ml of 
an overnight culture was harvested and lysed by the addition of one ml TRIzol. 
Following the addition of 200 µl chloroform and centrifugation (16,000 x g, 5 min, 
4°C), the upper aqueous phase was transferred to a fresh tube. The RNA in the 
aqueous phase was precipitated by the addition of 500 µl of isopropanol and pelleted 
by centrifugation (16,000 x g, 10 min, 4°C). The RNA pellet was washed with one ml 
of 70% ethanol, dried at 37°C and resuspended in 50 µl of DEPC treated water. 
4.4.2.2 Isolation of RNA using mirVanaTM miRNA Isolation Kit (Ambion)  
For the isolation of small RNA species (< 200 nt) the mirVanaTM miRNA 
Isolation Kit (Ambion) was used. Using a hand-held glass Teflon homogenizer, 0.1 g 
S. putrefaciens CN-32 cells were homogenized in 1 ml lysis buffer (containing 
guanidinium isothiocyanate) for 3 min on ice. After the addition of 100 µl miRNA 
HomogenateTM additive and incubation for 10 min on ice, the sample was 
phenol/chloroform extracted. To separate the total RNA into two fractions and enrich 
the small RNA species, the sample was brought in a first step to 25% ethanol to 
immobilize large RNAs on the glass-fiber filter. The small RNA species were 
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collected in the filtrate. The ethanol concentration of the filtrate was then increased to 
55% and passed through a second glass-fiber filter to immobilize small RNAs. Both 
RNA fractions were washed and eluted in 100 µl Elution Solution pre-heated at 
95°C. 
 
4.4.3 Quantitative and qualitative analyses of RNA  
The concentration of extracted RNA was determined spectrophotometrically, 
by measuring sample absorbance at 260 nm. The A260/A280 ratio was used as an 
indicator for RNA purity, as pure RNA preparations showed a ratio higher than 1.8, 
whereas ratios lower than 1.8 indicate possible contamination with protein or phenol. 
The integrity of purified RNA was checked by Urea-PAGE (S 4.4.4) or by northern 
blotting (S 4.4.5). 
 
4.4.4 Gel electrophoresis of RNA (Urea-PAGE) 
Gel electrophoresis of RNA was performed using urea-polyacrylamide gels. 8 
M urea was used to resolve the secondary structures of RNA and obtain separation 
based on the size of the RNA. To 8 M urea, 90 mM Tris pH 8.0, 90 mM boric acid, 2 
mM EDTA, 1.0% (v/v) ammonium persulfate (APS) and 0.1% (v/v) 
tetramethylethylenediamine (TEMED), varying concentrations (6% to 20%) of 
polyacrylamide (acrylamide / bisacrylamide, 40%, ratio 29:1) was added depending 
on the size of the applied RNA. The polymerized gel was assembled in the gel 
chamber (Mini Protean Tetra System, Biorad) and run in 1x TBE buffer (90 mM Tris 
pH 8.0, 90 mM boric acid and 2 mM EDTA) at 200 V for 1h. The RNA samples were 
mixed with 2x formamide loading dye (80% formamide, 10 mM EDTA, 0.05% (w/v) 
bromophenol blue and 0.05% (w/v) xylenecyanol) and incubated for 5 min at 95°C 
before applying them to the urea-polyacrylamide gel. The RNA bands were 
visualized by toluidine blue staining. 
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4.4.5 Northern blotting 
4.4.5.1 Transfer of RNA to a nylon membrane  
Using a semi dry electrophoretic transfer system, the RNA separated based 
on sizes on a urea-polyacrylamide gel were transferred to a positively charged nylon 
membrane (Roti®-Nylon Plus, Roth). As a preparation for transfer, the membrane 
was soaked for 1 min with DEPC treated water and equilibrated along with the gel in 
1x TBE buffer for 5 min. The transfer was performed for 2h at 25 V in a Biorad 
semidry apparatus. Following the transfer, the blot was washed in DEPC treated 
water to remove salts and the RNA was UV-crosslinked to the membrane.  
4.4.5.2 Labeling of oligonucleotide probes 
RNA probes for EMSAs and nuclease assays and DNA oligonucleotide 
probes for northern blotting (Table 6) were radiolabeled at the 5′ end using γ-[32P]-
ATP. 100 pmoles of the probe was 5′ labeled with γ-[32P]-ATP (5000 Ci/mmol, 
Hartmann Analytic) using 10U of T4 polynucleotide kinase (NEB, Ambion) at 37°C 
for 1h. The reaction was stopped by the addition of 2x formamide loading dye and 
separated on a 10% urea-polyacrylamide gel. The labeled probe was cut out of the 
gel after phosphorimaging, gel eluted and precipitated using ethanol. After 
resuspending the probe in 50 µl of DEPC treated water, its radioactivity was 
measured using a scintillation counter. 
4.4.5.3 Hybridization with labeled probes and visualization  
Upon hybridization with radiolabelled probes, specific RNAs were detected on 
a blot containing 10 µg of total RNA from S. putrefaciens CN-32. Therefore, the blot 
was initially pre-incubated with ULTRAhyb-Oligo hybridization buffer for 30 min at 
42°C to block non-specific binding sites. The probe (106 cpm/ml of hybridization 
buffer) was applied to the ULTRAhyb-Oligo buffer after incubation at 95°C for 5 min. 
After overnight incubation at 42°C, the blot was washed twice, with low stringency 
buffer (2X SSC + 0.1% (w/v) SDS) and with high stringency buffer (00.1X SSC + 
0.1% (w/v) SDS) at 42°C for 15 min to remove unbound probe. Overnight exposure 
of the blot to a phosphorimaging screen followed by phosphorimaging using a storm 
840 phosphorimager resulted in visualization of the bands. 
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4.4.6  Generation of specific RNA by in vitro transcription 
Fragments for RNA substrates (fragment size ~60-150 bp) were amplified via 
PCR using plasmid DNA listed in Table 5, purified after agarose gel electrophoresis 
and used as templates for RNA in vitro transcription. 
In vitro transcription to generate crRNAs was performed using T7 RNA 
polymerase in a standard reaction assay (20 µl) containing 500-1,000 ng purified 
PCR product. The reaction buffer contained 40 mM HEPES/KOH pH 8.0, 22 mM 
MgCl2, 5 mM dithiothreitol (DTT), 1 mM spermidine, 4 mM NTP mix and 30 nM of T7 
RNA polymerase. The samples were mixed, centrifuged briefly and incubated for 2h 
at 37°C. Addition of 2x formamide loading dye stopped the reaction and the products 
were separated on a 10% urea-polyacrylamide gel and visualization by toluidine blue 
staining. The RNA was gel eluted, precipitated using ethanol and resuspended in 50 
µl of DEPC-treated water. Final concentration of the RNA was determined 
spectrophotometrically (S. 4.4.3). For higher concentrations of RNA, in vitro 
transcription at a larger volume was performed. 
 
4.4.7 Nuclease assays 
The endoribonuclease activity of recombinant Cas6 and in vitro reconstituted 
Cas proteins were assayed using radiolabeled RNA as substrates. Labeling of the in 
vitro generated RNA substrate was performed as described in S 4.4.5.2. A standard 
nuclease assay contained 50 nM radiolabeled RNA substrates (CRISPR substrates 
or RNA controls) and 100-500 nM proteins in a reaction buffer of 50 mM Tris/HCl pH 
7.0, 100 mM NaCl, and 1 mM DTT. The reaction was initiated by incubating the 
sample at 30°C for 30 min and stopped by adding 2x formamide loading dye and 
boiling at 95°C for 5 min. Separation of the cleavage products was achieved via 10% 
or 20% Urea-PAGE and the bands were visualized using a storm 840 
phosphorimager.  
 
4.4.7  Electrophoretic Mobility Shift Assay (EMSA)  
Electrophoretic mobility shift assays were employed to investigate the nucleic 
acid-binding properties of proteins. It is a procedure that utilizes the slow migratory 
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behavior of a nucleic acid bound protein complex compared to free nucleic acid 
through a non-denaturing polyacrylamide gel (S. 4.5.3.2). To perform the assay, 50 
nM radiolabeled RNA was mixed with 100 -500 nM protein in a buffer containing 50 
mM Tris/HCl pH 7.0, 100 mM NaCl, and 1 mM DTT and incubated for 30 min at 
30°C. The sample was mixed with GelPilot loading dye (Qiagen GmbH) and applied 
to a 6% non-denaturing polyacrylamide gel. The gel was run at 10 W for 2 h and 
exposed to a phosphorimaging screen overnight. The bands were visualized using 
the storm 840 phosphorimager.  
 
4.4.8 qRT-PCR analysis  
To compare mRNA transcript levels between wild-type and deletion strains of 
S. putrefaciens CN-32 quantitative real-time polymerase chain reactions (qRT-PCR) 
were performed. cDNA was synthesized from the extracted DNA-free total RNA 
using the First Strand cDNA Synthesis Kit (Thermo Scientific). qRT-PCR was 
performed with the iQ SYBR Green Supermix Kit (Bio-Rad, Munich, Germany) using 
10ng of synthesized cDNA and gene specific primers (Table 6), designed with a 
specific annealing temperature of 59°C. The PCR was performed in a CFX96 Real-
Time PCR Detection System (Bio-Rad) using the following protocol: 
 
Step 1) 95°C – 3 min 
Step 2) 95°C – 10 sec 
Step 3) 59°C – 10 sec            x 40 
Step 4) 72°C – 30 sec/kb 
 
The PCR was also performed using primers against the 16S rRNA, which 
served as control. The specificity of the amplification was verified using the melting 
curve of the CFX96 Real-Time PCR Detection System. The calculation of the CT-
value (threshold cycle), which describes the cycle at which the fluorescence is higher 
than the background fluorescence, was done using the Bio-Rad CFX Manager 
Software. The expression levels of cas genes was depicted relative to the control 
16S rRNA. Three independent experiments were conducted and the mean of the 
values was used for the analysis. 
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4.5 Working with DNA 
4.5.1 Preparation of plasmid DNA from E. coli  
Plasmids used for cloning or sequencing analyses were prepared using the 
Qiagen plasmid mini kit or the Qiagen plasmid maxi kit according to the 
manufacturer′s instructions.  
 
4.5.2 Quantitative and qualitative analyses of DNA  
The concentration of DNA was determined spectrophotometrically by 
measuring the absorption of the sample at 260 nm. The purity of DNA was 
determined by the ratio of absorbance at 260 nm to 280 nm. An A260/A280 ratio of 1.8-
2.0 was observed in pure DNA preparations whereas a ratio lower than 1.8 indicated 
that the presence of potential contaminants.  
 
4.5.3 Electrophoresis of DNA 
4.5.3.1 Agarose gel electrophoresis of DNA  
Agarose gel electrophoresis was performed to separate DNA fragments 
based on size. Depending on the size of the DNA fragments, agarose gels of varying 
concentrations (1% to 2% (w/v) of agarose) in TAE buffer (40 mM Tris pH 8.0, 40 
mM acetic acid and 1 mM EDTA) were prepared. Ethidium bromide (final 
concentration: 0.5 µg/ml) was added to the gel mixture to visualize DNA, as it 
intercalates between base pairs of DNA or RNA molecules and emits fluorescence 
when excited by UV light. The DNA samples mixed with 6x DNA loading dye (10 mM 
Tris/HCl pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol, 60% glycerol and 
60 mM EDTA) were applied and electrophoresis were performed at 200 V in TAE 
buffer. 5 µl of a DNA marker containing a mixture of DNA fragments of known size 
and amount was also applied onto the gel. After the electrophoresis run, the DNA 
was visualized by exposing the gel to UV light using a Chemi-Doc-gel documentation 
system. The size of the separated DNA fragments was determined by comparing 
their relative positions to those of the DNA ladder. 
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4.5.3.2 Non-denaturing polyacrylamide gel electrophoresis of DNA (Native-PAGE) 
Electrophoretic separation of smaller DNA fragments (< 200nt) was performed 
under non-denaturing conditions using polyacrylamide gels (120). Depending on the 
size of the DNA fragment, the concentration of polyacrylamide (acrylamide / 
bisacrylamide, 40%, ratio 29:1) in the gel (90 mM Tris pH 8.0, 90 mM boric acid, 2 
mM EDTA, 0.03% (v/v) APS, 0.005% (v/v) TEMED) was varied between 4% and 
12% (v/v). The DNA samples mixed with 6x DNA loading dye were applied on to the 
gel. DNA marker containing a mixture of DNA fragments of known size was also 
applied onto the gel to size the fragments. The gel run was performed in 1x TBE at 
10 W for 1 h.  
 
4.5.4 Purification of DNA fragments 
The PCR amplification products were separated according to size on an 
agarose gel. The fragment of interest was cut out and extracted from the gel piece 
using the QIAquick gel extraction kit (Qiagen GmbH) following the instructions of the 
manufacturer. 
 
4.5.5 Polymerase chain reaction (PCR) 
The PCR technique was used for the amplification of specific DNA fragments 
in vitro. Two primers were designed such that they hybridize to the 5′ end of the 
coding and the noncoding strand, flanking the sequence of interest that has to be 
amplified. The elongation of these primers was catalyzed by the Phusion 
polymerase, which possesses proofreading capability and has a reduced mutation 
rate. A standard PCR reaction includes the following main steps:  
1) Denaturation: Heating the reaction at 95°C results in the melting of dsDNA 
into ssDNA (template). 
2) Primer annealing: Annealing or binding of the primers to their complementary 
DNA  
3) Elongation: Extension or elongation of the primer in the 5′ to 3′ direction. DNA 
polymerase catalyzes the elongation by addition of complementary 
nucleotides. 
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Amplification of the sequence of interest was obtained by repetition of the above 
steps (25-30x). One important factor that affects the yield and purity of PCR is the 
annealing temperature of the primers. The primers used for PCR are listed in Table 
6. 
4.5.5.1 Amplification of genomic DNA and plasmid DNA  
PCR amplifications from genomic or plasmid DNA was performed using the 
following reaction mixture: 
~50 µg template DNA  
250 µM dNTPs  
0.2 µM Fw. primer  
0.2 µM Rv. primer  
1 x concentrated GC buffer 
3% (v/v) DMSO 
1 U Phusion polymerase 
adjusted to 50 µl with water 
The reaction was performed in a thermal cycler (BioRad) using the following 
program: 
Step 1) 95°C – 60 sec 
Step 2) 95°C – 30 sec 
Step 3) 55-65°C – 30 sec  x 30 – 35 
Step 4) 72°C – 30 sec/kb 
Step 5) 72°C – 5 min 
4.5.5.2 Site directed mutagenesis  
Using the Agilent site-directed mutagenesis primer design platform, primer 
sets containing the desired mutations were designed (Table 6). Mutations were 
introduced in the plasmids by QuikChange site-directed mutagenesis (Stratagene) 
using the designed primers. The plasmids carrying the mutations were identified via 
sequencing. 
4.5.5.3 Overlap extension PCR 
In the overlap extension PCR (121), two PCR products with overlapping 
sequences are fused together and amplified to obtain a longer product. Two internal 
primers (b and c) and two external primers (a and d) are designed and in the first 
round of PCR, small DNA fragments are generated using, the primer combinations 
a-b and c-d. The PCR products were gel eluted (S 4.5.4), mixed together and using 
the external primer set a and d, a longer fused product was amplified. The primer 
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sets used for overlap extension PCR are listed in Table 6. 
 
4.5.6  Modification of DNA  
4.5.6.1 Restriction of DNA  
The restriction digestion of plasmid DNA and PCR products was carried out 
with appropriate restriction endonucleases in respective buffers as recommended by 
the manufacturer. To obtain digested product, reaction mixture containing 5-10 U 
enzyme/µg DNA was incubated at 37°C for 2 h.  
4.5.6.2 Ligation  
T4 DNA ligase enzyme catalyzes the formation of a phosphodiester bond 
between 5′-phosphate and 3′-hydroxyl termini of duplex DNA in the presence of ATP 
and hence used in ligation of a restricted DNA fragment to a vector DNA (122-124). 
Restricted plasmid DNA and restricted insert in 1:3 molar ratio where taken in a 
ligation buffer (400 mM Tris/HCl pH 7.8, 100 mM MgCl2, 100 mM DTT and 5 mM 
ATP). After the addition of 3 µl of T4 DNA ligase (1 Weiss-unit/µl), the reaction 
mixture was incubated overnight at 16°C and transformed into E. coli DH5α. 
4.5.6.3 5′ labeling of DNA oligonucleotides 
DNA oligonucleotide probes were radiolabeled using the procedure described 
in S. 4.4.5.2. 
 
4.5.7  Electrophoretic Mobility Shift Assay (EMSA)  
EMSA was performed to study the nucleic acid binding properties of a protein. 
To obtain the slow migration band on an EMSA, 50 nM of 5′ radiolabelled 
oligonucleotide primers was incubated with recombinant proteins or in vitro refolded 
complexes (100- 500 nM) in a buffer containing 50 mM HEPES/KOH pH 7.0, 50 mM 
NaCl, 5 mM MgCl2 and 5 mM MnCl2. The assay was performed at 30°C for 15 min, 
mixed with GelPilot loading dye (Qiagen GmbH) and applied to an 8% non-
denaturing polyacrylamide gel. To ensure specificity of the interaction, 1 µg of yeast 
RNA as a competitor was added to the assay. The migration bands were visualized 
by phosphorimgaing after an electrophoretic run at a constant 10 W for 2 h. 
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4.5.8  Nuclease assays 
The nuclease activity of recombinantly produced Cas3 and in vitro 
reconstituted Cas proteins were assayed using radiolabeled oligonucleotide 
substrates. Labeling of the oligonucleotide primers was performed as described in S 
4.4.5.2. The nuclease assay contained 50 nM radiolabeled oligouleotide (CRISPR 
substrates or DNA controls) and 100-500 nM proteins in a reaction buffer containing 
50 mM HEPES/KOH pH 7.0, 50 mM NaCl, 5 mM ATP, 5 mM MgCl2, 5 mM MnCl2, 
and 20 ng yeast RNA. The reaction was incubated at 30°C for 15 min, stopped by 
adding 2x formamide loading dye and boiling at 95°C for 5 min and separated via 
20% Urea-PAGE. Phosphorimaging was employed for the visualization of the 
cleavage products.  
 
4.6  Transformation 
4.6.1  Transformation of E. coli 
4.6.1.1 Preparation of competent E. coli DH5α and DH5α λpir cells  
Competent cells of E. coli (S. 2.3) were chemically prepared by using 
rubidium chloride (RbCl) and calcium chloride (CaCl2) (125). 100 ml 2x YT medium 
containing 10 mM MgCl2 and 10 mM MgSO4 was inoculated with 2 ml of an 
overnight culture of E. coli. The culture was grown at 37°C with constant agitation at 
200 rpm until OD600 of ~ 0.6 was reached. After cooling the culture on ice for 30 min, 
the cells were harvested by centrifugation (3000 x g, 10 min, 4°C). Subsequently, the 
cell pellet was gently resuspended in 33 ml chilled solution A (30 mM Potassium 
acetate pH 5.8, 100 mM RbCl, 50 mM MgCl2, 10 mM CaCl2 and 15% glycerol) and 
incubated on ice for 30 min. After centrifugation (3000 x g, 10 min, 4°C) the pellet 
was again gently resuspended in 5 ml chilled solution B (10 mM MOPS pH 5.8, 75 
mM CaCl2, 10 mM RbCl and 15% glycerol) and incubated for 30 min on ice. 100 µl 
aliquots of the resuspended solution was made and was used for transformation (S. 
4.6.1.3) or stored at -80°C. 
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4.6.1.2 Preparation of competent E. coli WM3064 cells 
Chemically competent cells of E. coli WM3064 were prepared using the Inoue 
method (126). 250 ml of SOB medium (0.5% yeast extract, 2% tryptone, 10 mM 
NaCl, 2.5 mM KCl and 20 mM MgCl2) supplemented with 300 µM DAP was 
inoculated with an overnight culture such that the starting OD600 of the culture was 
0.05. The cells were grown at 18°C with constant agitation at 200 rpm till an OD600 of 
~ 0.6 was reached. After cooling the culture on ice for 10 min, the cells were 
harvested by centrifugation (2,500 x g, 10 min, 4°C). The cells were gently 
resuspended in 75 ml of ice-cold TB-buffer (10 mM PIPES/KOH pH 6.7, 250 mM KCl 
and 15 mM CaCl2) supplemented with DAP, incubated on ice for 10 min and pelleted 
(2,500 x g, 10 min, 4°C). The cells were again resuspended in 20 ml of ice-cold TB-
buffer with DAP and 7% (v/v) DMSO and incubated for 10 min. After incubation, 200 
µl aliquots were prepared and used for transformation. Long-term storage was 
carried out at -80°C. 
4.6.1.3 Transformation of competent E. coli cells  
Plasmid DNA was gently mixed with 100 µl of competent E. coli cells and 
incubated on ice for at least 45 min. The cells were given a heat shock by incubating 
at 42°C for 45 sec followed by placing on ice for 1 min. 1 ml of LB medium was 
added and incubated at 37°C for about 45 min accompanied by shaking. 100 µl of 
transformed cells were plated on LB agar plates containing the respective antibiotics. 
Whereas the remaining 900-1000 µl cell suspension was centrifuged, resuspended 
in about 100 µl LB-medium and plated. Overnight incubation of LB agar plates at 
37°C resulted in colonies that were screened for positive clones carrying the 
recombinant plasmid using restriction digestion (S. 2.6.8.1) of isolated plasmid DNA 
(S. 2.6.2.1, S. 2.6.2.2). For the transformation of E. coli WM3064, media was every 
supplemented with DAP. 
 
4.6.3  Conjugation of S. putrefaciens CN-32 
E. coli WM3064 strain carrying the desired plasmid and S. putrefaciens CN-32 
were grown in 20 ml of LB media overnight (medium for E. coli WM3064 was 
supplemented with DAP and antibiotics for the plasmid). Equal OD600 of both strains 
were harvested and washed once with LB supplemented with DAP (LB-DAP). Both 
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strains were resuspended in 100 µl of LB-DAP, mixed and spotted as a single drop 
on LB-DAP plates. After overnight incubation at 30°C, the spot was dislodged from 
the plate and washed three times using plain LB. 100 µl of this mating culture was 
platted on LB plates supplemented with antibiotics and incubated at 30°C to screen 
for transformed S. putrefaciens CN-32. The presence of plasmid was confirmed 
through colony PCR or plasmid isolation and sequencing. 
 
4.7 Working with S. putrefaciens CN-32 
4.7.1  In-frame insertions and deletions 
4.7.1.1 Construction of in-frame insertion and deletion plasmids 
For in-frame deletions, 500 bp upstream and downstream to the gene of 
interest were PCR amplified using genomic DNA and gel purified. Using overlap 
extension PCR, the two fragments were fused and the final product was restriction 
digested and ligated to the suicide plasmid, pNPTS138-R6KT (kanR). Similarly for in-
frame insertions, an insert with the gene of interest and 500 bp upstream and 
downstream of the locus of interest were generated via PCR and ligated to the 
suicide plasmid. The generated suicide plasmids are listed in Table 5. 
4.7.1.2 In-frame insertion and deletion via homologous recombination 
The above-generated plasmids were conjugated into S. putrefaciens CN-32 
using E. coli WM3064 as a donor strain and due to homologous recombination, the 
insertion or deletion strains were generated. Single crossover integration was 
obtained by screening on LB kanamycin (LB-kan) plates lacking DAP. Single 
colonies were grown in plain LB to achieve the second homologous recombination 
and plated on LB plates containing 10% sucrose (v/v). Colonies lacking the plasmid 
were selected based on its kanamycin sensitivity and using colony PCR, were 
checked for target insertion or deletion. 
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4.7.2  Conjugation-based in vivo interference assay 
4.7.2.1 Construction of plasmids for conjugation  
Oligonucleotides that contained the protospacer and PAM sequences were 
designed such that on hybridization, the sticky ends of EcoRI and BamHI restriction 
sites flanked the ends of the protospacer sequence. These oligonucleotides were 
phosphorylated at the 5′ terminus (as described in S. 4.4.5.2 using non-labeled 
ATP), mixed and hybridized. The obtained DNA fragment was ligated to the 
linearized pBRR1MCS2 (kanR) vector. Insertion of the fragment was into the vector 
was confirmed by sequencing. The oligonucleotides used for the construction of 
these plasmids are listed in Table 6. 
4.7.2.2 In vivo interference assay 
These plasmids were conjugated into S. putrefaciens CN-32 wild-type and 
deletion strains using E. coli WM3064 as donor as described in S. 4.6.3. The S. 
putrefaciens CN-32 colonies containing the plasmid were obtained on LB-kan plates 
lacking DAP and counted. As a control, conjugation of S. putrefaciens CN-32 strains 
was performed with the empty plasmid and the colonies counted. The conjugation 
efficiency for a plasmid containing a protospacer in a strain was determined by 
taking the ratio of number of colonies obtained for this plasmid to the empty plasmid. 
Interference in this strain was observed if its conjugation efficiency was found to 
significantly lower than 1. 
 
4.8  Biochemical methods 
4.8.1  Heterologous production of Cas proteins in E. coli  
For the heterologous production of S. putrefaciens CN-32 proteins, the 
encoding genes were PCR amplified and cloned into expression vectors (Table 5). 
PCR was performed using Phusion DNA polymerase with genomic DNA of S. 
putrefaciens CN-32 serving as the template and the primers listed in Table 6. The 
sequences of the cloned genes were verified by sequencing and used for 
heterologous expression in E. coli BL21(DE3)pLysS.  
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4.8.2  Preparation, enrichment and purification of the recombinant enzymes  
4.8.2.1 Purification of the recombinant Cas3 protein 
Recombinant Cas3 was produced as a SUMO-tagged protein in E. coli 
BL21(DE3)pLysS. The cell pellet was resuspended in buffer containing 50 mM 
Tris/HCl pH 7.0, 10% glycerol and 300 mM NaCl (5 ml/g cells) and incubated on ice 
with lysozyme. The cells were lysed by sonication and the cell lysate was clarified by 
centrifugation (18,000 rpm, 20 min, 4°C). Clarified lysate was applied to a His-Trap 
Ni Sepharose column (GE Healtcare) and using a step gradient (20% imidazole 
steps) in imidazole concentration of the buffer on the ÄKTA protein purification 
system (GE Healtcare), the protein was eluted from the column. Fractions containing 
the protein were identified after SDS-PAGE and concentrated using vivaspin 
centrifugal concentrators. The concentration of the protein was determined using the 
Bradford assay (127).  
4.8.2.2 Purification of the recombinant Cas1821 protein 
Recombinant Cas1821 was produced as a SUMO-tagged protein in E. coli 
BL21(DE3) pLysS. The cell pellet was resuspended in buffer containing 100 mM 
KPO4 pH7.5, 500 mM NaCl, 10% glycerol and 20 mM imidazole (5 ml/mg) and 
incubated on ice for 4°C with protease inhibitor (1 ml per 50 ml of lysate), 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (serine protease inhibitor, 75 µl/ 
50 ml of lysate) and DNase I (0.05 mg/ml). The cells were lysed by sonication, 
clarified by centrifugation (18,000 rpm, 20 min, 4°C) and applied to a His-Trap Ni 
Sepharose column. Using a very steep gradient in imidazole concentration, the 
protein was eluted and dialyzed overnight at 4°C into 50 mM Tris/HCl pH 7.5, 300 
mM NaCl, 10% glycerol, 1 mM DTT and 1 mM EDTA. Addition of SUMO-protease 
during dialysis resulted in the cleavage of the SUMO-tag from the protein. Following 
a second dialysis step into 50 mM Tris/HCl pH 7.0, 100 mM NaCl, 10% glycerol, 1 
mM DTT and 1 mM EDTA for 3h at 4°C, the protein was applied to a Heparin 
Sepharose column and using a gradient in the salt concentration, the protein was 
eluted from the column. The purity of this protein was checked by SDS-PAGE and 
the concentration determined using the Bradford assay.  
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4.8.2.3 Purification of the recombinant Cas1822 protein 
Recombinant Cas1822 was produced as a CPD-tagged protein in E. coli 
BL21(DE3)pLysS. The cell pellet was resuspended in buffer containing 100 mM 
KPO4 pH7.5, 500 mM NaCl, 10% glycerol and 20 mM imidazole (5 ml/mg). The cells 
were lysed by sonication after incubation on ice for 30 min with lysozyme. After 
clarification of the cell lysate by centrifugation (18,000 rpm, 20 min, 4°C) the lysate 
was applied to a His-Trap Ni Sepharose column. A linear gradient in imidazole was 
used to elute the protein from the column and the eluted protein dialyzed into 50 mM 
Tris/HCl pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM DTT and 1 mM EDTA at 4°C. 
During dialysis, 100 µM of phytic acid was added to induce autocatalysis of the CPD-
tag from the protein. The cleavage of the tag was checked by SDS-PAGE and the 
protein concentration was determined using the Bradford assay. 
4.8.2.4 Purification of the recombinant Cas6f protein 
Recombinant Cas6 was produced with a C-terminal 6x His-tag in E. coli 
BL21(DE3)pLysS. The cell pellet was resuspended in buffer containing 50 mM 
Tris/HCl pH 8.0, 500 mM NaCl, 20 mM Imidazole, 5% glycerol, 0.01% triton X100 
and 1 mM DTT (5 ml/mg) and lysed via sonication. Cell lysate was clarified by 
centrifugation (18,000 rpm, 20 min, 4°C) and applied to a His-Trap Ni Sepharose 
column. The column was washed with the above buffer containing 100 mM imidazole 
and using a linear gradient in imidazole concentration, the protein was eluted. The 
purity of the protein was checked by SDS-PAGE and the concentration was 
determined using the Bradford assay. 
4.8.2.5 Purification of the variant Type I-F Cascade complex 
E. coli BL21(DE3)pLysS cells producing the interference complex were 
resuspended in buffer containing 50 mM Tris/HCl pH 7.0, 500 mM NaCl, 10% 
glycerol, 20 mM Imidazole and 1 mM DTT (5 ml/mg) and lysed via sonication. Cell 
lysate was clarified by centrifugation (18,000 rpm, 20 min, 4°C), applied to a His-
Trap Ni Sepharose column and eluted with a linear gradient in imidazole 
concentration. Fractions containing the complex were pooled, concentrated and 
further purified on a size-exclusion chromatography column equilibrated with 50 mM 
HEPES/NaOH, 150 mM NaCl and 1 mM DTT. The purity of the complex was verified 
by SDS-PAGE and the presence of RNA was detected by Urea-PAGE. The 
concentration of the complex was determined using the Bradford assay. 
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4.8.2.6 Inclusion body purification 
Due to a very low amount of recombinant protein in the soluble fraction, the 
proteins were purified from inclusion bodies, which are insoluble aggregates that are 
often formed during high-level production of recombinant proteins in E. coli. Inclusion 
bodies contain the respective protein in a highly enriched form and can be isolated 
by in vitro refolding techniques (128,129). For that purpose, 5 g of BL21(DE3)pLysS 
cells producing Cas1, Cas3, Cas1822 and Cas6 were resuspended in 25 ml buffer 1 
(100 mM Tris/HCl pH 7.0, 1 mM EDTA). Lysozyme (1.5 mg/g cells) was added to the 
cell suspension, mixed gently and incubated for 30 min at 4°C. The cells were lysed 
via sonication and incubated for 30 min at 25°C after the addition of 10 µg/ml DNase 
and 3 mM MgCl2. Following the addition of 0.5 vol of buffer 2 (60 mM EDTA, 6% 
Triton X-100, 1.5 M NaCl pH 7.0) and incubation for 30 min at 4°C on a rocking 
platform, the inclusion bodies were pelleted by centrifugation (31,000 x g, 10 min, 
4°C). The supernatant was discarded and the inclusion bodies were resuspended in 
40 ml buffer 3 (100 mM Tris/HCl pH 7.0 and 20 mM EDTA) and again centrifuged 
(31,000 x g, 10 min, 4°C). The obtained inclusion bodies were stored at -20°C for a 
maximum period of two weeks.  For solubilisation of inclusion bodies, 50 mg of the 
pellet was dissolved in 5 ml buffer 4 (100 mM Tris/HCl pH 8.0, 6 M guanidine 
hydrochloride (Gua-HCl), 100 mM DTT and 1 mM EDTA) and incubated for 2-4 h at 
25°C on a rocking platform. Subsequently the pH was decreased to 3-4 with 250-300 
µl 1M HCl and the sample centrifuged (10,000 x g, 10 min, 4°C) to remove cell 
debris. To eliminate DTT from the sample, two dialysis steps were conducted. First, 
the protein mixture was dialyzed for 2 h at RT against 500 ml buffer 5 (4 M Gua-HCl 
and 10 mM HCl), then dialyzed overnight at 4°C against 500 ml 4 M Gua-HCl. The 
protein concentration was determined using the Bradford assay. The solubilized 
protein was stored at -80°C.  
4.8.2.7 Reconstitution of the Cas proteins from inclusion bodies  
The protein complex was refolded by removal of the denaturing agent by 
stepwise dialysis against a native Gua-HCl free buffer (129). Equal amounts (300 
µg) of each solubilized protein Cas1, Cas3, Cas1822 and cas6 (S. 4.8.2.6) and 300 
µg of the purified Cas1821 were mixed with 10 ml of buffer 6 (50 mM Tris/HCl pH 
7.0, 3.5 M Gua-HCl, 10% glycerol, 300 mM NaCl, 10 mM MgSO4 and 1 mM DTT). 
The solution was mixed thoroughly and dialyzed at 4°C against 200 ml of buffer 7 
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(50 mM Tris/HCl pH 7.0, 3 M Gua-HCl, 10% glycerol, 300 mM NaCl, 10 mM MgSO4 
and 1 mM DTT). By decreasing the concentration of the denaturing agent in the 
dialyzing buffer in regular steps (by 0.5 M Gua-HCl every 2h), the complex was 
reconstituted. After dialysis, the protein sample was centrifuged (14,000 x g, 15 min, 
4°C) and its concentration was determined using the Bradford assay. The purity of 
refolded complex was checked by SDS-PAGE. 
 
4.8.3  Western blot analysis 
4.8.3.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
For the separation of proteins based on their molecular weight, discontinuous 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed (130). The SDS polyacrylamide gels are composed of a stacking gel (125 
mM Tris/HCl pH 6.8, 5% (v/v) Acrylamide, 0.1% (w/v) SDS, 0.03% (v/v) APS and 
0.005% (v/v) TEMED) and a separation gel (375 mM Tris/HCl pH 8.8, 15% (v/v) 
Acrylamide, 0.1% (w/v) SDS, 0.03 % (v/v) APS, 0.005% (v/v) TEMED). The 
acrylamide concentration in the separating gel was varied between 10 and 15% (v/v) 
depending on the desired separation of the protein samples. Samples mixed with 2x 
SDS loading dye (125 mM Tris/HCl pH 6.8, 20% glycerol, 4% (v/v) SDS, 10% (v/v) 
β-mercaptoethanol and 0.01% (w/v) bromophenol blue) were applied to the gel after 
boiling at 95°C for 5 min. The run was carried out in a gel chamber (Mini Protean 
Tetra System, Biorad) containing 1x SDS running buffer (25 mM Tris/HCl pH 8.0, 
190 mM glycine and 0.1% (v/v) SDS) at 200V for 50 min. After separation, 
Coomassie based staining solution (Roth) was used to visualize the protein bands 
on the gel. 
4.8.3.2 Transfer and detection of the proteins 
Using a semi dry electrophoretic transfer system, the proteins separated on 
an SDS-polyacrylamide gel were transferred to a nitrocellulose membrane 
(Amersham Hybond ECL Nitrocellulose Membrane; GE Healthcare). As a 
preparation for transfer, the membrane was soaked for 1 min in methanol and then 
equilibrated along with the gel in transfer buffer (50 mM Tris/HCl pH 7.5, 39 mM 
Glycine, 0.0375% (w/v) SDS and 20% Methanol) for 5 min. The transfer was 
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performed for 90 min at 25 V in a Biorad semidry apparatus. Following the transfer, 
the membrane was washed in water and incubated with blocking solution (50 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 0.02% (v/v) Tween20 and 5% (w/v) Skimmed milk 
powder) at room temperature (RT) for 1 h and then the antibody solution containing 
the anti-His-HRP antibody (1: 10,000; Anti-His Mouse monoclonal IgG2b antibody; 
Life Technologies) was added and incubated at RT for 45 h. The membrane was 
washed three times with the blocking buffer for 10 min and chemiluminescence 
reaction was conducted using the Roti®-Lumin plus reagent (Roth) according to the 
supplier′s protocol. The film (Medical X-Ray Screen; CEA, Assamstadt) was exposed 
for 60 s – 6 h depending on the signal strength and developed in a developing 
machine (QX-60; Konica, Munich). 
 
4.8.4  Co-immunoprecipitation 
The interaction partners of His-HA-Cas1821 were identified using Dynabeads 
coupled to anti-HA antibodies. The coupling of the Dynabeads (Invitrogen, 50 
µl/sample) to anti-HA antibodies (3 µl/ sample, anti-HA monoclonal mouse Ig2b 
antibody, Life technologies) was achieved by incubating the mixture at 4°C for 1 h. 
Before the addition of the antibodies, the Dynabeads were equilibrated with 1xPBS 
buffer. To remove unbound antibodies, the Dynabeads were washed twice with 
1xPBS buffer and resuspended in buffer containing 50 mM Tris/HCl pH 7.5, 300 mM 
NaCl and 10% glycerol. These beads were then added to S. putrefaciens cell lysate 
and incubated at 4°C for 2 h with gentle rotation. After incubation, the Dynabeads 
were pelleted and washed five times in buffer containing 50 mM Tris/HCl pH 7.5 and 
300 mM NaCl to remove unbound proteins. The bound proteins were eluted by 
resuspended the beads in 2x SDS loading dye and boiling for 5 min at 95°C and 
separated via SDS-PAGE. Presence of the protein of interest was detected by 
western blot analysis and its interaction partners were identified by mass 
spectrometry. 
 
4.8.5  Mass spectrometry 
Interaction partners that were obtained during co-IP experiments were 
identified using mass spectrometry and were performed in collaboration with Dr. Jörg 
Kahnt at the MPI for Terrestrial Microbiology, Marburg. 
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4.8.6  Electron Microscopy 
Prof. Dr. Andreas Klingl and Dr. Thomas Heimerl of the Philipps-Universität 
Marburg, performed the Electron Microscopy of the Cas1821 filaments and the 
variant Type I-F Cascade complexes. 
 
4.8.7 Sequencing of RNA 
Preparation of RNA-seq libraries and the sequencing of RNA libraries by 
Illumina HiSeq2000 approach were performed at the Max-Planck genome Centre, 
Cologne. 
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Appendix 
Appendix 1: 
Phylogenetic analysis of Cas1821 and its homologs with proteins from the Cas7 
family (protein sequences obtained from Makarova et al., 2011). Cas1821 and its 
homologs were found to cluster together and shared an evolutionary relationship 
with Cas7 from Type I-F. 
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Appendix 2: 
Phylogenetic analysis of Cas1822 and its homologs with proteins from Cas5 protein 
family (protein sequences obtained from Makarova et al., 2011). Cas1822 and its 
homologs were found to cluster together and share an evolutionary relationship with 
Cas5 from Type I-C. 
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Appendix 3:  
List of proteins identified by mass spectrometry after Co-IP studies of Cas1821-His-
HA and ΔH-NS strains of S. putrefaciens CN-32. In yellow are the proteins that were 
identified for both the strains. 
 Protein name 
 List of proteins identified for His-HA-Cas1821 strain 
1 Signal recognition particle-docking protein FtsY  
2 DNA gyrase subunit B  
3 ATP-dependent protease La  
4 Putative ABC transporter ATP-binding protein  
5 Tonb-dependent receptor  
6 30S ribosomal protein S1  
7 Elongation factor G  
8 Atpase  
9 GTP-binding protein LepA  
10 Preprotein translocase subunit SecA  
11 Molecular chaperone DnaK  
12 ATP-dependent helicase HepA  
13 Amidophosphoribosyltransferase  
14 Carbamoyl-phosphate synthase L chain, ATP-binding  
15 Thiamine biosynthesis protein ThiI  
16 DEAD/DEAH box helicase domain-containing protein  
17 CTP synthetase  
18 DNA mismatch repair protein MutS  
19 1-deoxy-D-xylulose-5-phosphate synthase  
20 Ribose-phosphate pyrophosphokinase  
21 Hypothetical protein Sputcn32_0667  
22 Molybdopterin oxidoreductase  
23 Dihydrolipoamide acetyltransferase  
25 Hypothetical protein Sputcn32_1449  
26 GTP-binding protein TypA  
27 DNA-dependent helicase II  
28 Transcription termination factor Rho  
29 MotA/TolQ/ExbB proton channel  
30 Gtpase ObgE  
31 Cell division protein FtsZ  
32 Outer membrane channel protein  
33 Aromatic hydrocarbon degradation membrane protein  
34 FliI/YscN family atpase  
35 Porin  
36 30S ribosomal protein S3  
37 Ribose-phosphate pyrophosphokinase  
38 Flagellin domain-containing protein  
39 Rod shape-determining protein MreB 
40 Hypothetical protein Sputcn32_1821  
41 Flagellin domain-containing protein  
42 Ompa/MotB domain-containing protein  
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43 Recombinase A  
 List of proteins identified for ΔH-NS strain 
1 ATP-dependent protease La  
2 Putative ABC transporter ATP-binding protein  
3 30S ribosomal protein S1  
4 DNA gyrase subunit B  
5 Signal recognition particle-docking protein FtsY  
6 Elongation factor G  
7 Ribose-phosphate pyrophosphokinase  
8 GTP-binding protein LepA  
9 dihydrolipoamide acetyltransferase  
10 Amidophosphoribosyltransferase  
11 CTP synthetase  
12 TonB-dependent receptor  
13 Preprotein translocase subunit SecA  
14 Prolyl-tRNA synthetase  
15 ATP-dependent helicase HepA  
16 GTPase ObgE  
17 Cell division protein FtsZ  
18 Transcription termination factor Rho  
19 ATP-dependent protease ATP-binding subunit HslU  
20 Signal recognition particle protein  
21 Aromatic hydrocarbon degradation membrane protein  
22 Aldehyde dehydrogenase  
23 Na(+)-translocating NADH-quinone reductase subunit F  
24 Na(+)-translocating NADH-quinone reductase subunit A  
25 MotA/TolQ/ExbB proton channel  
26 DEAD/DEAH box helicase domain-containing protein  
27 Porin  
28 Flagellin domain-containing protein  
29 Ribose-phosphate pyrophosphokinase  
30 Flagellin domain-containing protein  
31 Rod shape-determining protein MreB  
32 Recombinase A  
33 OmpA/MotB domain-containing protein  
34 Septum site-determining protein MinD  
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Die in dieser Arbeit präsentierten Ergebnisse wurden von mir selbständig 
ohne andere als die hier aufgeführte Hilfe durchgeführt. Im Folgenden werden 
weitere an dieser Arbeit beteiligten Personen sowie deren experimentellen Beiträge 
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